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Abstract
Machine learning and deep learning methods have been increasingly applied to solve
challenging and important bioinformatics problems such as protein structure pre-
diction, disease gene identification, and drug discovery. However, the performances
of existing machine learning based predictive models are still not satisfactory. The
question of how to exploit the specific properties of bioinformatics data and couple
them with the unique capabilities of the learning algorithms remains elusive. In this
dissertation, we propose advanced machine learning and deep learning algorithms to
address two important problems: mislocation-related cancer gene identification and
major histocompatibility complex-peptide binding affinity prediction.
Our first contribution proposes a kernel-based logistic regression algorithm for
identifying potential mislocation-related genes among known cancer genes. Our algo-
rithm takes protein-protein interaction networks, gene expression data, and subcel-
lular location gene ontology data as input, which is particularly lightweight compar-
ing with existing methods. The experiment results demonstrate that our proposed
pipeline has a good capability to identify mislocation-related cancer genes.
Our second contribution addresses the modeling and prediction of human leuko-
cyte antigen (HLA) peptide binding of human immune system. We present an allele-
specific convolutional neural network model with one-hot encoding. With extensive
evaluation over the standard IEDB datasets, it is shown that the performance of our
model is better than all existing prediction models. To achieve further improvement,
we propose a novel pan-specific model on peptide-HLA class I binding affinities pre-
diction, which allows us to exploit all the training samples of different HLA alleles.
iv
Our sequence based pan model is currently the only algorithm not using pseudo se-
quence encoding — a dominant structure-based encoding method in this area. The
benchmark studies show that our method could achieve state-of-the-art performance.
Our proposed model could be integrated into existing ensemble methods to improve
their overall prediction capabilities on highly diverse MHC alleles.
Finally, we present a LSTM-CNN deep learning model with attention mechanism
for peptide-HLA class II binding affinities and binding cores prediction. Our model
achieved very good performance and outperformed existing methods on half of tested
alleles. With the help of attention mechanism, our model could directly output the
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In 1902, Archibald Garrod published the paper The Incidence of Alkaptonuria: A
Study of Chemical Individuality which confirmed the inheritance of the disorder alka-
ptonuria (better known as black urine disease) in men. But it would wait 90 years
later, a mutation in HGD gene were demonstrated and elucidated as the genetic basis
of this disorder [9, 37]. The number of disease genes discovered has grown steadily in
past years [37]. The large-scale genome sequencing and high-throughput sequencing
provide a vast amount of data and bioinformatics has changed the way searching for
disease genes. In the work of [44], researchers rediscovered nearly all known cancer
genes of 21 tumor types in a large-scale genomic analysis. Beyond this, researchers
are targeting more specific underlying mechanisms of how disease gene affect the
proteins’ subcecullar locations [51, 77].
With the advent of genomic sciences, rapid DNA sequencing, combinatorial chem-
istry, cell-based assays, and automated high-throughput screening (HTS), the way we
design and discover drugs to diseases has also been dramatically shaped and enriched
[16]. With known drug target (usually protein receptor or enzyme) and associated
structure, virtual screening is a widely used computational technique to filter small
molecule candidates from a large number of libraries of compounds [30, 83]. Actually,
virtual screening has become an integral part of the drug discovery process [27]. Usu-
ally, virtual screening in drug discovery consists of docking, which decides where to
bind, and scoring, which reports the binding affinity of a protein-peptide interaction.
1.2 Scope of the Proposed Research
In this dissertation proposal, we focus on two specific topics:
1) As described before, there are quite a few effective models and methods which
can identify cancer genes. With so many cancer genes discovered, people are digging
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into them trying to find out what’s the effect of these cancer genes in cellular activi-
ties. In this work, we are interested in one type of cancer genes whose mutations or
abnormal expressions lead to mislocation of its translated proteins. And we propose
a computational pipeline to help identify mislocation related cancer genes.
2) Another part of our work is major histocompatibility complex-peptide (MHC-
peptide) binding prediction. More specifically, we are working on class I MHC-peptide
binding affinity prediction. The topic interests us because recent cancer immunother-
apy studies show that peptide-based vaccine is a promising for cancer treatment and
it requires a more reliable and improved computational tool to predict which peptide
will bind to MHC proteins [74, 56, 101, 79, 1]. In this dissertation, we present two
models to address this problem. The first one is an allele-specific model which out-
performs all existing methods. Next, we propose a pan-specific model which could
be used to predict on all known MHC class I alleles.
1.3 Structure of the Dissertation
In chapter 2, we present a pipeline of identifying mislocation-related cancer genes
and show the potential gene candidates we found in our experiments. In Chapter 3,
we introduce the CNN model we proposed for peptide-MHC I binding prediction and
show our performance comparison with other methods. In Chapter 5, we present our
sequence based pan-specific model and list the results on benchmark dataset. Finally,
we conclude our work and discuss future work in Chapter 6.
3
Chapter 2
Mislocalization-related Disease Gene Discovery
4
2.1 Introduction
Discovering disease or cancer genes and understanding their underlying pathologi-
cal mechanisms are the major challenges of biomedical research. In the past decades,
many efforts have been devoted to disease gene discovery using either high-throughput
techniques [45] or computational disease gene prediction methods [55, 17]. However,
these approaches usually report dozens or even hundreds of candidate genes while the
experimental validation of many candidates is often an expensive and time-consuming
task. To address this issue, many computational candidate gene prioritization algo-
rithms have been developed by exploiting the biomedical knowledge available about
the disease of interest and related genes [32]. For example, network information
and heterogeneous phenomic and genomic datadata sources have been used to rank
candidate genes [72, 105, 111, 22, 33]. A recent work [32] integrates a plethora of
phenomic and genomic data to pinpoint disease genes including disease phenotype
similarity derived from the Unified Medical Language System (UMLS) and seven
types of gene functional similarities calculated from gene expression, gene ontology,
pathway membership, protein sequence, protein domain, protein-protein interaction
and regulation pattern, respectively. Their methods thus covered a total of 7,719
diseases and 20,327 genes. However, such studies brought limited insights into the
pathological mechanisms due to their generic nature.
Protein Subcellular Location Prediction
The Eukaryotic cell, as the basic structural and functional unit of eukaryotic living
organisms, contains numerous proteins located in different subcellular organelles or
compartments, such as nuclei, mitochondria, cytoplasm, and Golgi apparatus (Fig-
ure 2.1). Binder et al. developed a comprehensive database to incorporate all data
sources of subcellular localization [11]. Protein translocation is key for a cell to func-
tion normally because proteins must be transported to their targeted compartment to
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exert their functions. The precise trafficking and translocation of cytosolic proteins to
their final destinations are crucial for the maintenance of appropriate cell functions
and activities. Proteins are typically directed to compartments by short peptide
sequences that act as targeting signals. Translocation to the proper compartment
allows a protein to form the necessary interactions with its partners and take part
in biological networks such as signaling and metabolic pathways. If a protein is not
localized to its correct intracellular compartment, either the reaction performed or
information carried by the protein does not reach the proper site, causing either inac-
tivation of central reactions or misregulation of signaling cascades, or the mislocalized
active protein has harmful effects by acting in the wrong place. This work is focused
on identifying cancer genes that may cause their translated proteins mislocation in
cells.
The protein sequence contains the information regulating protein trafficking [67].
Based on proteins’ target destinations, there are two major mechanisms of translo-
cation: post-translational translocation and co-translational translocation [29, 86,
78, 102]. Proteins translocating to peroxisomes, mitochondria or the nucleus are
called post-translational translocation [102, 85, 92, 94, 104]. For proteins translocated
into the endoplasmic reticulum during synthesis, a process known as co-translational
translocation is used [102]. Subcellular localization determines the access of proteins
to interacting partners and the post-translational modification machinery and enables
the integration of proteins into functional biological network [29].
However, proteins not always go to the correct locations and mislocalized proteins
can lead to disease like Alzheimer’s disease, kidney stones and cancers [29]. This is
because failure to be transported to the correct subcellular compartment can have
adverse effects, as protein location is fundamental to the functioning of cells and
regulatory control in the disease [65]. In [98], three major mechanisms were identified
that can lead to protein mislocation: mislocation through alterations of the protein
6
trafficking machinery [24], mislocation through altered protein targeting signals [43]
and mislocation through changes in protein interaction or modification [29].
Figure 2.1 Subcellular Protein Sorting
2.1.1 Related Work
In the past decade, high-throughput methodological approaches such as cancer genome
sequencing, RNA sequencing, cancer exome sequencing and functional genomics [55]
have led to the identification of multiple cancer-causing genes, genetic alterations and
deregulated pathways. Identifying and understanding the underlying mechanisms are
the foundation for cancer diagnostics, therapeutics, clinical-trial design and selection
of rational combination therapies [61, 66, 35, 107, 60, 95]. These hight-throughput
experimental approaches plus the computational disease gene prioritization tools can
greatly help to pin-down the range of cancer genes for experimental studies.
In a recent genome-wide study, Lawrence et al. [46] analyzed 4742 human cancers
and their matched normal-tissue exome sequences accross 21 tumor types. This large-
scale genomic analysis identified nearly all known cancer genes in 21 tumor types.
Additionally, out of 81 "novel" candidate cancer genes, 33 genes are not previously
7
reported as significantly mutated in cancer. Based on close examination, they found
at least 21 novel genes with strong and consistent connections to cancer. With more
cancer sequencing, it is expected that a comprehensive catalog of cancer genes can
be discovered to enable physicians to select best therapy fore each patient. However,
experimental studies of these newly identified candidate genes are needed to verify
and uncover the underlying mechanisms of these cancer-causing genes.
Lawrence et al.’s study [46] showed the power of tumor-normal pairs of the genome
sequence data for discovery of candidate cancer genes, which inspired us to explore
how to apply the tumor-normal pairs of gene expression data for identifying the cancer
genes that may lead to mislocalization of proteins. Actually, Pinto et al. showed that
dynamic redistribution of multitudinous proteins to different subcellular locations
in response to cellular functional state is a crucial characteristic of cellular function
that seems to be at least as important as overall changes in protein abundance [77].
Laurila and Vihinen [43] applied bioinformatics methods to investigate the effects of
known disease-related mutations on protein targeting and localization by analyzing
over 22,000 missense mutations in more than 1500 proteins with two complementary
prediction approaches. However, many of the localization prediction algorithms that
they used are not sensitive enough to capture the subtle sequence mutation to give
different localization predictions. Lee et al. [51] proposed an integrative computa-
tional framework for mapping conditional location and mislocation of proteins on
a proteome-wide scale. They mapped the locations of over 10,000 proteins in nor-
mal human brain and in glioma, out of which over 150 have a strong likelihood of
mislocation under glioma. Fifteen of these mislocations have been confirmed. The
most common type of mislocation occurs between the endoplasmic reticulum and the
nucleus.
High-throughput sequencing has almost identified all known and potentially new
cancer genes based on tomour-normal tissue sequences. It implies that the major
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task now is on computational or experimental techniques to elucidate the underlying
pathologic mechanisms of these cancer-causing genes. In this work, we are interested
in discovering cancer genes which impact humans due to their mislocation within
the cell. Lee’s pipeline was proved successful in discovery of mislocalized proteins in
cancer. However the data needed in Lee’s pipeline were complex including sequences,
chemistry, motifs and gene function ontology [50, 51]. Considering the data source and
lacking of ready-to-use server or software, it is very difficult to use their pipeline to do
large scale screening. When predicting conditional localization, we found that in Lee’s
method the only evidence source that has changed between normal and disease status
is gene expression. It is thus natural to develop methods for conditional localization
prediction based only on the changing factor, gene expression. Compared to Lee’s
approach, our approach only depends on gene expression files and gene ontology,
which makes it applicable for broader range of cancers. As shown in Figure 2.2, our
pipeline used gene ontology and gene expression files to predict proteins’ subcellular
locations in disease/tumor and normal states. Based on predicted locations of two
states, we can identify proteins whose subcellular locations change dramatically. The
reason we only use gene expression data as input is that we are trying to predict the
condition-specific mislocations. If any gene in our candidates is a known cancer gene,
it may cause cancer due to its mislocation within the cell. Our work aims to open
a way to explore the complex relationship between protein subcellular locations and
disease phenotypes.
2.2 Methodology
The main idea of this study is to predict subcellular localizations of proteins in normal
and disease states cells and then filter proteins that are mislocated in disease state
cells. Then we can filter mislocation proteins translated from known cancer genes
and mark these cancer genes as mislocation-related genes. The overall procedure of
9
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Figure 2.2 Pipeline of KLR model for subcellular localization prediction. (a)
Based on expression values, maximal information coefficient was calculated of two
proteins. Then we got a co-expression matrix (N ×N) which was considered as a
condition-based PPI network. (b) In gene ontology database, we extracted
subcellular ontology information of any possible protein appeared in gene expression
profile to generate the subcellular location annotated matrix (M × 13). (c) KLR
predictor took two matrix as input to predict the probabilities on 13 subcellular
locations of each protein appeared in gene expression file. The result was a N × 13
subcellular location annotated matrix.
our approach:
1. Generate co-expression matrices using MIC [80] package based on gene expres-
sion files for normal and disease states.
2. Use KLR logistic regression model [48] to predict the conditional subcellular
locations of all proteins in both states.
3. Compare and rank the probability discrepancy of localizations of all proteins.




We generate the protein-protein interaction network based on two proteins inter-
action database: DIP (Released on 2014/04/27)[84] and HPRD (Version number:
Relase 9) [39]. DIP provides specific datasets for different species and we downloaded
Homo sapiens dataset which includes 3651 proteins and 5534 interactions. There are
11269 proteins and 36398 interactions in HPRD database (Table 2.1). Combining
two databases, we constructed a 12516 × 12516 PPI network matrix in which each
element mi,j represents the interaction status between protein i and j:
mi,j =

1 if protein i and j have interactions;
0 otherwise;
(2.1)
Table 2.1 Source of evidence data: protein-protein interactions.




Subcellular Location Annotation Matrix
We obtained subcellular localization annotations of human proteins from GOC web-
site [5]. The datasets contains 44,900 annotated proteins. We then collected the
proteins that have at least one of 13 subcellular locations as shown in Table 2.2. We
screen the GOC database and 6270 proteins were found appearing in our PPI network
previously constructed. Then we have the subcelluar location annotation matrix in
11
which each row is a protein p’s annotation array ap[l1, ..., l13] where:
ap[li] =

1 protein p is annotated at subcellular location li;
0 otherwise;
(2.2)
Table 2.2 Subcellular locations.














Gene Expression Profiles and Co-expression Network
Five types of cancer gene expression profiles and normal human expression profiles
were downloaded from the NCBI Gene Expression Omnibus(GEO) Database (Ta-
ble 2.3). For each of these files, we applied KNN Impute to estimate the missing
values. The KNN Impute was downloaded from [97]. All expression profiles were
quantile normalized. If multiple probes were mapped to one gene, we use their av-
erage values to combine the records. For each dataset we obtained, we split samples
into two categories (if applicable): disease samples and normal samples. Then, we
generate corresponding co-expression matrices for both normal and disease samples,
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respectively. A co-expression score ci,j of two genes i and j is calculated:
ci,j =

0 MIC(Ei, Ej) < 0.5
1 otherwise
(2.3)
where Ei and Ej are observed expression values arrays of genes i and j respectively.
Her we use Maximal Information Coefficient (MIC) [80] to represent the correlation
of two genes’ expression levels.
Table 2.3 Gene Expression Profiles of 6 Cancers
Cancer GEO dataset Samples
Acute myeloid leukemia GSE9476, GSE9476 25 (disease), 38 (normal)
Bladder GSE3167, GSE48276, GSE3239, GSE1595 110 (disease), 21 (normal)
Breast GSE27567, GSE20437 61 (disease), 49 (normal)
Colorectal GSE21510 31 (disease), 25 (normal)
Diffuse large B-cell lymphoma GSE14938, GSE43677 32 (disease), 42 (disease)
2.2.2 KLR Logistic Regression Model
In our previous work, we developed a diffusion kernel-based logistic regression (KLR)
model to predict proteins’ subcecullar localizations based on the locations of all other
proteins within function linkage network. Our results showed that KRL has an out-
standing performance on prediction of proteins’ subcecullar localizations [63]. This
method has the unique advantage of considering the location labels of all related pro-
teins [49]. The diffusion kernel provides means to incorporate all neighbors (rather
than direct neighbors) of proteins in the network. It also allows each protein anno-
tated with multiple subcellular locations.
The protein subcellular localization prediction vis KLR model can be formulated
as follows. Given a protein-protein interaction network or a gene co-expression net-
work (briefly named network in later description) consists of N proteins X1, ..., XN
and n of them have location labels. In KLR model, the probability of one protein Xi
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without labels locating at a specific subcellular location is given by:
P (Xi) =
1
1 + e−γ+δM0(Xi)+ηM1(Xi) (2.4)








j 6=i and Xj=1
K(Xi, Xj) (2.6)
In M0(i) and M1(i), K(i, j) is the kernel function calculating the similarity between
two proteins in network and K(i, j) is defined as:




1 if protein Xi interacts with protein Xj
0 otherwise
(2.8)
and τ is the diffusion constant, a hyper parameter. We trained our KLR model with
protein-protein network and subcelullar annotation matrix with Maximum Likelihood
Estimation. To prediction, the gene co-expression network and subceullar annotation
matrix will be used as input.
2.3 Experiments
2.3.1 Case Studies: Discovery of Possible Mislocalized Cancer Related
Proteins Across Several Types of Cancers
We test our pipeline on gene expression files from 6 cancers’ data: Acute myeloid
leukemia, Bladder, Breast, Colorectal and Diffuse large B-cell lymphoma. The gene
expression files used are listed in Table 2.3. For each cancer, we filter potential
mislocalization-related genes from known cancer genes following below steps:
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1. Use proposed pipeline to get predicted probabilities of each protein in 13 sub-
cellular locations for both normal and tumor states. Let Pa indicates protein
a’s probabilities on 13 subcecullar locations under normal state and Pa[i] rep-
resents a’s probability locating on ith location of 13 subcellular locations. Let
P′a represents its localization probabilities under disease state.
2. Calculate M Pa by subtracting P
′
a from Pa. If M Pa[i] is a relatively large
negative value, it indicates that protein a may be missing from location i in
disease state. And if M Pa[i] is a relatively large negative value, it may imply
that the protein a may be mislocated to the subcellular location i in disease
state.
We reported the proteins with either at least 10% probability change or ranked within
top 4 proteins with at least 5% probability change. We observed that in most cases,
the cancer genes not selected in our method usually had much lower probability
change with a p-value of less than 0.002% for t test scores of all M P on a subcellular
location i. So the simple threshold approach adopted here to selecting mislocated
proteins is sufficient to distinguish the potential mislocalized cancer genes from other
genes. Table 2.4 lists potential candidate genes we filtered.
Acute Myeloid Leukemia
In Acute myeloid leukemia, we used 25 samples in tumor state and 38 samples in
normal state as our analysis data. They were all from hematopoietic cells. Our
pipeline identified two genes DNMT3A and STAG2 with high localization change
that are reported as cancer genes in [45]. DNMT3A, in our model, was predicted
mislocating from Golgi apparatus in disease cell (2.96%) comparing with normal cells
(6.29%). Another covered candidate gene is STAG2, which was predicted mislocating
to two locations: Nucleus where had 41.29% probability in normal and had probability
15
Table 2.4 Potential mislocalized cancer gene candidates identified by proposed
method.





















































64.45% in disease and Endoplasmic reticulum where had 5.52% probability in normal
and had probability 12.12%
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Bladder Tumor
Our results used 9 normal bladder tissue samples and more than 110 disease bladder
tissue samples. The cancer gene DDX5 was predicted to have a 36.19% probability
of being localized to Nucleus in normal tissues. The predicted probability of being
localized to Neucleus in disease tissues was 52.25% with an increase of more than
40%. At the same time, DDX5 had 8.60% probability in normal and 3.80% in disease
localizing on Endoplasmic reticulum with an decrease of more than 55%. So based
on this probabilities changes, we can make a speculation that in bladder tumor cell
DDX5 mislocalized from Endoplasmic reticulum to neucleus. Tumor suppressor gene
RB1 was predicted with a high probability change in its subcellular location from cell
cortex to other locations (3.39% in normal, 0.98% in disease). Recently a study [8]
showed that in breast cancer mutated RB1 will lead to their localization to nucleus.
We also observed in our prediction the increase of probability localization in nucleus
(48.23% in normal, 57.27% in disease). Our predicted localization change of RB1
maybe caused by its mutation. Also protein ELF3 was predicted mislocating to
Mitochondrion where its location probability changing from 8.16% in normal state to
15.31% in cancer state.
Breast Cancer
After analyzing 61 disease samples and 49 normal samples, We obtained several can-
didate proteins that probably mislocate under cancer states. At subcellular location
Cilium, protein ERBB2’s predicted localization probability decreased from 63.68%
(normal) to 55.87% (disease). Also its probability localization on Nucleolus had a
decreasing from 6.41% (normal) to 1.99% (disease). And at the same time, ERBB2’s
probability localization on Golgi apparatus had an increasing from 8.65% (normal)
to 11.37% (disease). These observations could indicate that some ERBB2 proteins in
breast cancer cells mislocalized from Cilium and Nucleolus to Golgi apparatus. Pro-
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tein ERBB3 had similar mislocation activity from Cilium (52.77% in normal, 44.78%
in disease) and Nucleolus (9.60% in normal, 3.05% in disease) to Golgi apparatus
(8.21% in normal, 10.75% in disease).
Colorectal Tumor
For colorectal tumor, we had 31 tumor samples and 25 normal samples. Protein
PIK3CA was observed in our prediction mislocating from Golgi apparatus (11.17%
in normal, 4.81% in disease) to Cytosol (27.74% in normal, 45.84% in disease). Pro-
tein GOT1 was predicted mislocating from Peroxisome where its location probability
decreased from 5.09% to 0.84% and from Endoplasmic reticulum where its location
probability decreased from 10.95% to 3.99%.
Diffuse Large B-cell Lymphoma
In Diffuse large B-cell lymphoma test, we used 42 normal samples and 32 disease sam-
ples. Protein CD70 was predicted missing from Nucleus (59.45% in normal, 35.96%
in disease) and at the same time its probability in Plasma membrane increased from
6.41% to 39.84%. So we speculated that some CD70 proteins may mislocate to Plasma
membrane from Nucleus in cancer cells. Protein CREBBP was also predicted hav-
ing mislocation activity that from Mitochondrion to Golgi apparatus. Its predicted
probability in Mitochondrion decreased from 25.64% in normal to 6.26% in disease
and the probability in Golgi apparatus increased from 3.95% to 7.62%. Besides,
protein MAP2K1 was observed mislocating to Cytosol (38.22% in normal, 66.17%
in disease). Protein B2M and protein EZH2 were predicted mislocating from Golgi
apparatus (12.90% in normal, 5.90% in disease) and Centrosome (23.92% in normal,
6.90% in disease), respectively.
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2.3.2 Rediscovery of Mislocalized Proteins in Glioma
In the work of Lee [51], a proteome-wide method was proposed to predict mislocalized
proteins under glioma tumor. They used sequence, chemical properties, motifs, and
function information of proteins as the basic features. Condition-dependent dynamic
network features were generated by assigning different weights to each neighbor of a
protein, depending on their similarity in gene expression profiles. Based on the basic
features and dynamic network features, they computed a CLM score for each protein,
listing the quantitative probability that the protein is located in each location under
each condition. Mislocations are identified by calculating differences in degrees of
probabilities across conditions. Their prediction result showed that their model can
successfully identify potential mislocation proteins under tumor conditions. However,
their approach requires many kinds of data resources which might not be available
for some proteins. Since the condition-dependent information is only contained in the
gene expression data, we wanted to test our model on the same gene expression data
to see if we can rediscover mislocalized proteins under glioma. We used GEO dataset
used by Lee’s team which contained normal, low and high states. In order to find
possible mislocalized proteins, firstly, our pipeline was used to predict location proba-
bilities of 13 subcellular locations of each protein for each status. For each protein, we
selected the location with highest probability as its predicted location in that status.
After we obtained a protein’s location probabilities in all normal and disease states,
we just picked up proteins having different locations under normal and disease states.
Totally, we found 230 proteins predicted as mislocalized proteins among 11500 pro-
teins. And for 157 proteins predicted as potentially mislocalized under glioma in Lee’s
paper, we rediscovered 31 proteins of them in our 230 predicted candidates having
same mislocation activity. Among rediscovered 31 proteins, TBX19 was experimen-
tally verified mislocation from endoplasmic reticulum to nucleus within glioma cell
in Lee’s paper. 31 proteins predicted by both Lee’s and our work with same misloca-
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tion activities: PSPN, TMEM132A, ARF5, TIA1, TIMM8A, OBP2A, CIC, OLFM2,
CPSF3L, DUSP14, PPM1B, SEC13, SSBP3, PEX13, THPO, RCAN2, TTN, WNT6,
TBX19, DAP, GEM, ATIC, DCPS, PROC, PAX1, SSB, TYMS, CCDC116, FTL,
CBLL1 and PLK3.
2.4 Chapter Summary
In this work, we have developed an approach for discovering mislocation related can-
cer genes based on aberrant gene expression data and diffusion kernel based logistic
regression for subcellular localization prediction. Our approach is complementary to
high-throughput genomic sequencing approaches for cancer gene detection by pro-
viding the means for understanding the pathological mechanisms. The experiments
showed that our approach has identified several interesting cancer genes reported by




Peptide-HLA class I Binding Prediction With
Allele specific CNN model
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3.1 Introduction
Major Histocompatibility Complex (MHC) proteins located on cell surface play a
critical role helping immune system recognizing pathogens. MHC proteins bind to
peptide fragments derived from pathogens and display them on the cell surface for
recognition by the appropriate T cells [57]. There are two major types of MHC (named
human leukocyte antigen (HLA) for human): class I and class II. HLAs class I present
peptides from inside the cell while HLAs class II present antigens from outside of the
cell to T-lymphocytes [103]. Peptides binding to HLA-I proteins will be recognized
by Cytotoxic T lymphocytes, which is a fundamental activity of immune system.
As shown in 3.2, endogenous antigens are first cleaved into peptide fragments by
the proteasome, which are then generally translocated by the transporter associated
with antigen processing (TAP) into the endoplasmic reticulum (ER). Then, HLA-I
molecules bind certain peptides and present them to cytotoxic T lymphocytes (CTL)-
stimulating cellular immunity [110]. The schematic structure of HLA class I is shown
in Figure 3.1. As shown in the figure, HLA class I molecules are heterodimers contains
two polypeptide chains: α and β2-microglobulin. Only the α chain is polymorphic
and encoded by a HLA gene. The α1 and α2 domains hold to make up a groove for
peptides binding while the α3 domain interacts with the CD8 co-receptor of T-cells
[103].
The genomic regions encoding HLA class I are highly diverse. As of Aug. 2017,
IPD-IMGT/HLA database [82] contains more than 12,000 HLA class I alleles. How-
ever, binding specificities of most HLA-I alleles have not been experimentally char-
acterized because it costs immense amount of financing and time. Thus, a large
number of computation methods were proposed on peptide-HLA Class I binding pre-
diction [38, 108, 12, 71, 76, 26, 40]. Generally, current computational methods for
peptide-HLA class I binding affinity prediction can be grouped into two categories:
allele-specific and pan-specific models. Allele-specific models are trained with only
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Figure 3.1 Schematic representation of HLA class I. Reproduced from wikipedia
the binding peptides tested on a specific allele and a separate allele-specific binding
affinity prediction model is needed for each HLA allele. Allele-specific models have
the advantage of good performance when sufficient number of training peptide sam-
ples are available. In pan-specific models, binding peptides of different alleles are all
combined to train a single prediction model for all HLA alleles. Typically, a pan-
specific model uses binding affinity data from multiple alleles for training and could
predict peptide binding affinity for the alleles that may have or have not appeared
in the training data. In Figure 4.1, we show the difference between allele-specific
methods and pan-specific methods.
In this chapter, we propose an allele-specific convolutional neural network model
(DeepMHC) targeting peptide-HLA class I binding affinity prediction and we show
that our method obtains better performance than all existing methods. First, we
review state-of-the-art methods in Section 3.2. Then we introduce our proposed allele-
specific model in Section 3.3. At the end of this chapter, Section 3.4, we compare
our performance with existing methods and do analyzing of our results and proposed
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method.
Figure 3.2 Simplified diagram of HLA class I pathway. Reproduced from
wikipedia.org
3.2 Related work
Existing prediction models for peptide-MHC I binding prediction can be classified into
two major categories: allele-specific model and pan-specific model. Allele-specific
prediction models are trained with binding data to a single allele and the trained
model can only be used to predict peptides binding to this allele. NetMHC [58] and
SMM [76] are representative ones with competitive performance. In this chapter, we
propose an allele-specific method based on convolutional neural network (CNN). We
compare its performance with both allele-specific and pan-specific methods. Pan-
specific methods take binding data of multiple alleles in a same supertype [87] and
MHC contacting environment data to train a model and the trained model could
be used to predict on not only input alleles but also alleles with few or even no
known binders [110]. Currently, outstanding pan-specific methods for MHC-I include
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NetMHCPan [26] and PickPocket [108]. In next chapter, we’ll introduce a pan-specific
method.
3.2.1 Deep Neural Network Methods
Currently, we just find few publications involving with deep neural network:
HONN [42] applied a Gaussian restricted Boltzmann machine(RBM) based deep
neural network (DNN) and a semi-RBMs based feed-forward high-order neural net-
work(HONN) to peptide-MHC I binding prediction. A BLOSUM encoding is used
to encode peptides into 180-dimensional continuous vectors.
HLA-CNN [99] is a newly reported model applied convolutional neural network
on this problem. It used distributed representation encoding a amino acids peptide
into a 15-dimensional vector. Then encoded vectors are fed into a network consisting
of two convolutional layers and one fully connected layer.
JHU-CNN proposed a CNN model using one-hot encoding[10]. Their model uses
different size of 1D convolutional filters on input sequences and concatenates convo-
lutional layers’ output into a single tensor and then feeds this concatenated tensor
into a multiple-layer fully connected neural network.
Comparison with these methods are described in section 3.4.3.
3.3 Methodology
3.3.1 Peptide sequence encoding
We use one-hot encoding approach to transform a amino acid sequence into a tensor
representation. As shown in Figure 3.3, each amino acid of the peptide is encoded by
a sparse column vector of dimension 20 with corresponding component set to 1 and
remaining 19 components set as 0. With the one-hot representation, there are still
two different ways to map the encoded matrix to a tensor in implementation level.
One is to map the input matrix as a 20-channel 1-row 2D tensor (or 20-channel 1D
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tensor), as is done in our proposed approach. Another way is to map the input matrix
as a single channel 20-row 2D tensor. In section 3.4.5, we compare and analyze two
different encoding ways’ performance.
PAD PAD A L T L S P Y Y K PAD PAD
A 0 0 1 0 0 0 0 0 0 0 0 0 0
C 0 0 0 0 0 0 0 0 0 0 0 0 0
D 0 0 0 0 0 0 0 0 0 0 0 0 0











































T 0 0 0 0 1 0 0 0 0 0 0 0 0
V 0 0 0 0 0 0 0 0 0 0 0 0 0
W 0 0 0 0 0 0 0 0 0 0 0 0 0
Y 0 0 0 0 0 0 0 0 1 1 0 0 0
Figure 3.3 One-hot encoding example of protein sequence ALTLSPYYK.
3.3.2 Convolutional Neural Network
We proposed a CNN model composed of two stacked convolutional layers, one max-
pooling layer, and one fully connected layer as shown in Figure 3.4. Of two convolution
layers, both has 512 convolution filters of size 1× 2 and 1× 3 respectively. Adam [41]
is used as the optimization algorithm for training the networks.
The convolutional layers: For each convolutional layer, it has 512 filters. These
filters will scan the peptide sequence from left to the right on 20 channels. We use S
to denote the encoded single row, 20-channel 2D tensor from a peptide sequence. It
shape will be (1, 13, 20) where 13 is the padded encoding length for a peptide sequence
with 9 or 10 length. F represent one of the 512 convolution filter tensors with shape
(1, 2, 20) which indicates that every filter has a 1× 2 receptive field for each channel.
Then the output tensor D with a shape (1, 12) from a convolution operation between










Max-pooling layers: The pooling layers are used for summarizing the activa-
tions of adjacent neurons. Different from the convolution layers in which the con-
volution filters move along the sequence by stride size of 1 with overlapping, the
nonoverlapping pooling is applied with a stride size (1, N) to reduce the dimension of
the input sequence and thus the number of model parameters. Two commonly used
poolings are Average-Pooling and Max-Pooling. Here the max-pooling layers are used
in our CNN models for summarizing the activations of adjacent N neurons by their
maximum value. In our model, we chose 2 as the N value. For a input tensor A with
shape (1, L), the output tensor P with shape (1, L/N) is calculated from:
Pi,j = maxm∈[i,i+N ],n∈[j,j+N ](Am,n) (3.2)
A L T L S P Y Y K





























(1) (2) (3) (3)* (4)
Figure 3.4 Network Architecture of Proposed CNN Model.
3.3.3 Datasets and Evaluation Metrics
To ensure fair comparison with existing approaches, we used the IEDB training
and test datasets released on the IEDB website. These datasets can be found at
http://tools.iedb.org/main/datasets/. We trained on MHC-I alleles with at least
about 2000 training samples from BD2013. The details of training datasets are listed
in Table 3.1. The evaluation dataset were downloaded from IEDB’s weekly bench-
mark dataset [96]. We download all dataset from 2014-03-21 to 2016-12-09 combining
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test samples according to alleles, sequence lengths and measure types. We separate
the evaluation datasets into two groups: one with affinity scores: IC50 and t1/2
(Table 3.3) and another one with binary affinity labels (Table 3.2).
Metrics we use to evaluate the performance are: area under the receiver oper-
ating curve (AUC), the Spearman rank correlation coefficient (SRCC) and Pearson
correlation coefficient (Pearson).
3.3.4 Allele-specific Training and Evaluation Protocol
The network structure is shown in Figure 3.4 and we use Mean Squared Error (MSE)
as the loss function. In the output layer, sigmoid activation is used to give the output
value. The labeled values in BD2013 are measured in IC50 which are distributed in
a huge real value space (0.0 v 80000.0). Considering this, we convert IC50 to pIC50
via equation 3.3 and we use pIC50 values as training labels in our experiments.
pIC50 = −log10(IC50) (3.3)
Training. First, we configure a CNN model described in section 3.3.2 and train
this model running up to 5000 epochs. Before each training epoch, training samples
are randomly split into training and validation sets following 9:1 ratio. The training
stops if the minimum validation loss haven’t reduced for 100 epochs (known as early
stop) or reaches 5000 epochs.
Cross-validation Evaluation. For each allele’s training data, we split them into
5 folds. For sequences in each fold held out as the test set, we applied the trained
CNN model to predict their affinity values. This process is repeated 5 times for all 5
folds. And then the Pearson correlation coefficients of all peptide samples of a MHC-I
allele are recorded.
Benchmark Evaluation. For each peptide sequence in the benchmark dataset,
we applied the 5 trained cross-validation models of peptide’s targeting allele and
predict 5 affinity values for one peptide sequence. And then the average of these
28
predicted values from all 5 models is set as the final predicted pIC50 for the peptide
sequence. Finally, the predicted pIC50 values are converted back into IC50 values
based on Equation 3.3.
3.4 Experiments
3.4.1 Performance of DeepMHC on MHC-I Binding Affinity Prediction
Cross-validation Results
The 5-fold cross-validation performances of the CNN models on all MHC-I alleles
are listed in Table 3.1. The Pearson scores range from 0.48 to 0.92. Our CNN
models achieved Pearson scores of more than 0.8 for 27 out of the 37 alleles. We
also found that most of the low-performance scores are from the alleles with fewer
number of peptide sequences (< 1000), which indicates that sufficient number of
peptide sequences are required for our CNN models to achieve good performance. It
is also found that all these low-performance allele dataset consist of peptide sequences
of length 10.
Benchmark Testing Results
Results of benchmark dataset are showed in Table 3.4 for peptides of 9-length and
Table 3.5 for peptides of 10-length. We sorted results by the combination of alleles,
sequence lengths (9 or 10) and measure types (IC50 or t1/2). Methods in these two
tables are: NetMHCpan [26], SMM [76], ANN [71], ARB [12], NetMHCcons [38],
SMMPMBEC [40], IEDBconsensus [64] and PickPocket [108].
Table 3.4 shows the comparison results on 9-length sequences. Few methods listed
in IEDB weekly benchmark dataset are omitted in this table because it doest not have
either any best results or complete prediction results. From Table 3.4, we can safely
say that our method performs overall better than others for obtaining 6 highest AUC
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scores, 8 highest SRCC scores and 7 highest Pearson scores of 15 testing entries. And
in only 6 test entries, our model didn’t obtain any best results among three metrics.
Also the average scores of our methods are still the best which indicating that our
proposed convolution network model has a stable prediction capability and could fit
in different alleles. The state-of-the-art NetMHCpan utilized pan-specific strategy
and trained each alleles’s samples on a set of artificial neural networks with 22 to
86 hidden neurons with 3 types of input encoding ways and then pick the best 15
networks [26]. Comparing with NetMHCpan, our allele-specific method fixed a neural
network structure and encoded sequences in the same way but our model performed
better more than half of the all test cases comparing AUC scores. Of 4 test entries
where our model didn’t get best results on AUC scores, HLA-A*02:02 (IC50), HLA-
A*24:02 (IC50) and HLA-B*07:02 (IC50 and t1/2), our performance were still either
very close to best results or among the top 3. For alleles HLA-A*02:03 (IC50), HLA-
B*58:01 (IC50), HLA-B*68:01 (IC50 and t1/2), HLA-B*57:01(IC50), we analyze the
prediction results and give following possible reasons our model could not obtain
better performance.
• Sample size. In the Table 3.1, HLA-B*68:01 just has 2036 training samples of
9 length sequences. It is well known that in order to obtain a good prediction
capability for deep neural network, the training sample size should be large
enough letting the model to do the optimization for its tons of parameters. So
the trained model may not be fitted well on this kind of cases.
• Misleading testing data. In the training dataset BD2013, IEDB combines
KD (thermo-dynamic constant), IC50 and EC50 together representing as IC50
since IC50 and EC50 measurements can approximate KD. And we found in
weekly benchmark data, there are some sequences appeared in training data
but contradict to the training labels dues to different measuring techniques. For
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example, the sequence ELAAHQKKI targeting to allele HLA-A*02:03. In the
training data, it is labeled with value 2650 (radioactivity dissociation constant
KD). In the weekly testing data, it is labeled with value 1.0 (radioactivity half
maximal inhibitory concentratio IC50). When we were testing, our method and
all other benchmark methods significantly failed on predicting this sequence’s
IC50 value. Since we followed the same method in [96] marking sequence as
negative if its IC50 < 500.0 nm, this kind of samples would drag the AUC
scores down for all models. In test entry HLA-A*02:03 (IC50), our model gave
a highest related prediction with a 0.62 Pearson score and we found among
105 testing sequences, there are 14 sequences appeared in training data with
contradicting labels. This maybe a big reason we failed on this kind of cases.
Table 3.5 shows performance comparison of benchmark dataset on 10-length se-
quences. From this table we can find that our model performs much better than all
other comparing methods with 4/5 best AUC scores, 5/5 best SRCC scores and 2/5
best Pearson scores. And in test entries HLA-A*02-01(t1/2), HLA-A*02-03(IC50)
and HLA- A*68-02(IC50) we have a pretty large leading margin. Also, the alleles in
Table 3.5 where we almost obtained all the best results also are the same alleles in
Table 3.4 where we obtained some good results. This indicated that our model could
capture the basic feature representation across in different length sequences.
3.4.2 Performance of DeepMHC on MHC-I Binding Prediction
To evaluate how DeepMHC performs on binary MHC-peptide binding prediction,
we trained a set of convolution neural network models over the MHC allele peptide
datasets of length of 9 with binary binding labels. The architectures of these models
are exactly as described in previous section except that the binary entropy loss func-
tion instead of MSE is used and the outputs are binary labels instead of real-value
binding affinity. We then evaluate their prediction performance on the external test
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datasets in Table 3.2. The prediction performances for all the datasets are shown in
Table 3.6.
First, we find that our DeepMHC models based on raw amino acid sequences
are competitive compared to other algorithms that depend on sophisticated feature
engineering. Out of 10 allele datasets, DeepMHC achieves top performance on 4
datasets, which is better than NetMHCpan, SMM and ANN methods. Out of the
remaining 6 datasets, DeepMHC obtains competitive results on 4 datasets (HLA-
A*02:01, HLA-A*68:01,HLA-B*07:02, HLA-A*31:01) with AUCs differences of less
than or equal to 0.04 compared to the top scores. But for cases like HLA-B*27:05 and
HLA-A*24:02, our performance is much worse, which can be partially attributed to
the reasons as mentioned in Section 3.4.1. To further explore the reasons, we plotted
the ROC curves of DeepMHC compared to NetMHCpan on these two datasets in
Figure 3.5. It is found that our models do not perform as well as NetMHCpan does
when the false positive rate is less than 0.2.
(a) HLA-B*27:05 (b) HLA-A*24:02
Figure 3.5 ROC curves of prediction results on benchmark data with binary labels
of allele HLA-B*27:05 and HLA-A*24:02.
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3.4.3 Comparison with Other DNN and CNN based approaches
HONN
Since there’s no available code for HONN, we trained another set of allele-specific
models on dataset BD2009 and tested these models on dataset BLIND. BD2009 and
BLIND were described in the HONN paper to train and evaluate the HONN model.
Table 3.7 shows the performances comparison between DeepMHC and HONN. The
AUC scores of HONN were directly obtained from its supporting material. From the
table we can say that on dataset BLIND, our model and HONN have a very similar
performance. Of all 29 test entries, on 15 test entries both model have same AUC
scores. In the rest entries, our model has 6 better results and HONN has 8.
JHU-CNN
JHU-CNN gives trained models and codes, we tested theirs models on the same
weekly benchmark dataset on all available alleles. The results are showed in Table
3.8. From this table, of all 20 testing entries, we obtained 12 better AUC scores, 13
better SRCC scores and 10 better PRCC scores. This shows that our method is a
better modeled structure for peptide-MHC I binding problem.
HLA-CNN
HLA-CNN tested their model on recent weekly benchmark data from IEDB. We
extract our prediction results for those testing sequences and compared the AUC and
SRCC. Results are shown in Table 3.9. The table displays a trend that HLA-CNN
performed better on AUC metric with 7 better AUC scores of 9 testing entries and
our model is better on SRCC metric with 7 better SRCC scores. A possible reason
is that HLA-CNN uses binary cross entropy as the loss function for their training.
Some studies indicated that cross entropy could improve performance of classification
[47].
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3.4.4 Transfer Learning on MHC Alleles with Small Number of Samples
A major issue in MHC-I binding prediction is that some alleles have small-size sample
sets. This makes it challenging to train accurate allele-specific prediction models. And
in deep learning, it is well known that a relative large dataset is critical for better
performance. An effective approach to address this issue is to use transfer learning,
which improves a learner from one domain by transferring information from a related
domain [13]. In this experiment, We would like to explore if transfer learning can
improve the prediction performance of DeepMHC on alleles with small number of
training samples. To verify this approach, we picked two alleles: HLA-A*02:01 and
HLA-A*02:02. We chose these two alleles because: i) According to [88], most HLA-
A alleles can be clustered in to 6 supertypes. HLA-A*02:01 and HLA-A*02:02 are
clustered into same supertype A02. So we can assume that HLA-A*02:01 and HLA-
A*02:02 share similar preference for binding peptide sequences to a certain degree. ii)
The HLA-A*02:01 dataset has the most training samples (9051) and HLA-A*02:02
has 2465 training samples. This is an idea situation to verify transfer learning’s
effectiveness.
We trained 5 models for HLA-A*02:02 following the same procedure described
before in a 5-fold cross validation way except that before we start to train a model,
we initialized the model’s weights of its first convolutional layer as the same weights
of first convolutional layer from one of the 5 pretrained models of allele HLA-A*02:01.
Figure 3.6 shows the performance comparison of affinity benchmark dataset of allele
HLA-A*02:02 on testing on models with and without transfer learning. We found
that the model trained with transfer learning has achieved a much better prediction
performance. The AUC has increased to 0.79 from 0.73; the SRCC reaches 0.72 from
0.66; and the Pearson improves from -0.03 to 0.01. If we compare these improved
metrics of allele HLA-A*02:02 with other methods’ reported in Table 3.4, this transfer
learning based model achieved the best results on test dataset HLA-A*02:02(IC50).
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Such significant performance improvement by transfer learning may be partially due
to the fact that we were actually doing a good initialization of weights for the first
convolutional layers by reusing the weights from the pretrained CNN models of HLA-
A*02:01. It is increasingly recongized that proper initiallization of the weights of the
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Figure 3.6 Performance comparison of benchmark dataset of allele HLA-A*02:02
testing on model without transfer learning (Without TL) and model with transfer
learning (With TL).
3.4.5 Comparison of Protein Sequence Encoding Schemas for One-Hot
Encoding
Unlike images naturally encoded as 2D multi-channel matrices, amino acid sequences
require us to chose proper encoding method to transfer them into tensors for deep
neural networks. In this section, we explore whether different encoding methods will
effect the prediction performance for peptide-MHC I binding prediction.
In previous experiments, we adopted a single row 20-channel encoding schema.
Here we are evaluating a single-channel 20-row encoding schema and compared its
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performance to 20-channel encoding schema. For first encoding schema, a protein
sequences is encoded into a tensor object with width of 13, height of 1 and depth
(channel) of 20. In the single-channel encoding, the amino acids sequence is repre-
sented as a tensor with width of 13, height of 20 and depth of 1. For single-channel
encoding schema, we constructed a compatible CNN model for the input tensors.
As illustrated in Figure 3.7, we first encode a 9-length sequence into a 20 × 9 × 1
dimension input tensor. Each row encoded the corresponding amino acid position.
Then the input tensor was feed to (1) convolution layer which has 512 filters with 2
× 2 receptive field size. Next in layer (2), output tensor of (1) is applied by a Max
Pooling layer with a 2 × 2 window. After Max Pooling, another convolution layer
(3) with 252 filters of 2 × 2 receptive field size is applied to the pooling layer output.
Then do pooling operation. A flatten operation is applied on the layer (4)’s output
and a 1D vector with 1008 dimension is obtained. This vector is feed to the fully
connected layer (4) which has 200 hidden units.
We configured a model as described above and following same training and evalu-
ation procedure in section 3.3.4 for allele HLA-A*02:01. We tested the trained model
with 20-row encoding schema (2D matrix encoding) on benchmark dataset of allele
HLA-A*02:01 and compare it with our previous model’s performance. The results
are showed in Figure 3.8. As shown in the Figure, the 2D matrix encoding model
performs worse in all three metrics comparing with previous 20-channel encoding
model. A possible explanation is that when we encode a sequence into a 2D matrix,
we manually fixed the spatial relationships of 20 types amino acids. When a convolu-
tion filter is searching the frequent patterns in this 2D matrix, it will be influenced by
this pre-fixed spatial arrangement. In images, the spatial arrangement of pixel values
are natrual and meaningful. However, in our 2D matrix encoding, we had to chose 1
of C2020 possible arrangements of 20 amino acids. If we initialize convolutional filters
with same strategy but with different arrangements of 20 types amino acids in en-
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coding matrix, the final filters learned may be dramatically different. By contrasting,
in the 20-channel model, a convolutional filter will have 20 receptive fields for each
channel and each field is search the feature patten in its channel independently. So if
we initialize convolutional filters with same strategy, no matter how we arrange the
relative order of 20 amino acids in terms of channels, the final filters learned should
be always similar. That is to say, 20-channel encoding schema model is more stable
during backpropagation.
Figure 3.7 Comparison results on benchmark dataset for allele HLA-A*02:01 on
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AUC
Figure 3.8 Network Structure of Single-Channel 20-Row Encoding ethod.
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3.4.6 Exploring Network Structure’s Effect on Peptide-MHC I Binding
Prediction Performance
Before we fixing our final structure of CNN model in Figure 3.4, we did some exploring
of different network structures with variant depth and number of convolution filters.
Our experiments showed that for our problem a wider network performs much better
than a narrow network and the depth does not influence performance very much.
First, we evaluated how the number of filters of two convolutional layers affects
the prediction performance. We configured a set of CNN models as described in
Figure 3.4 but varied the number of filters of two convolution layers by setting it
as 25, 50, 100, 250 and 512. Then we trained and evaluated these models on allele
HLA-A*02:01 following same procedure described in section 3.3.4. The results are
showed in Figure 3.9. From the figure we can see that, the model with 512 filters
performs better than other models with large leading margins on all metrics: SRCC,
Pearson and AUC. In the convolution layer, the number of filters decides the diverse
and amount of features we want to capture. Each filter is supposed to capture a
basic feature representation of input tensors. The results implies that a wider model
is much more helpful improving performance for our targeting problem.
Then, we explored if a deeper network could improve the performance. The
model shown in Figure 3.4 consisting of 4 layers: conv-pool-conv-full. We constructed
another two types of model:
• 6-layer model: conv-pool-conv-pool-conv-full
• 7-layer model: conv-pool-conv-pool-conv-pool-conv-full
We trained and evaluated 6-layer model and 7-layer model with same procedure on al-
lele HLA-A*02:01. Results are shown in Figure 3.10 and no significant differences were
observed. A possible reason is that the dimension of our input tensor is 1×13×20.
After too many layers, the intermediate tensors will be very short in width. So after
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Figure 3.9 Comparison of performance of models with different number of




































In this chapter, we proposed an allele-specific CNN model on peptide-MHC I binding
prediction and showed its leading performance comparing with existing methods. We
also analyzed few factors that may affect performance of our model. We found that
a wider neural network is good for our targeting problem and argued that 20-channel
encoding model is more stable comparing with 20-row encoding model.
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HLA-A*02:01 IC50 9 9051 3273 5778 0.91
HLA-A*03:01 IC50 9 5488 1378 4110 0.87
HLA-A*11:01 IC50 9 4544 1363 3181 0.89
HLA-A*02:03 IC50 9 4428 1543 2885 0.90
HLA-B*15:01 IC50 9 4101 1187 2914 0.86
HLA-A*31:01 IC50 9 3945 1015 2930 0.89
HLA-A*01:01 IC50 9 3902 539 3363 0.81
HLA-B*07:02 IC50 9 3868 1061 2807 0.80
HLA-A*26:01 IC50 9 3766 409 3357 0.87
HLA-A*02:06 IC50 9 3733 1522 2211 0.88
HLA-A*68:02 IC50 9 3672 835 2837 0.90
HLA-B*08:01 IC50 9 3027 715 2312 0.86
HLA-B*58:01 IC50 9 2984 655 2329 0.88
HLA-B*40:01 IC50 9 2824 478 2346 0.89
HLA-B*27:05 IC50 9 2811 443 2368 0.92
HLA-A*30:01 IC50 9 2565 736 1829 0.89
HLA-A*69:01 IC50 9 2558 248 2310 0.82
HLA-B*57:01 IC50 9 2529 384 2145 0.84
HLA-B*35:01 IC50 9 2514 821 1693 0.92
HLA-A*02:02 IC50 9 2465 1119 1346 0.90
HLA-A*24:02 IC50 9 2395 496 1899 0.89
HLA-B*18:01 IC50 9 2315 230 2085 0.81
HLA-B*51:01 IC50 9 2239 233 2006 0.82
HLA-A*29:02 IC50 9 2110 532 1578 0.86
HLA-A*68:01 IC50 9 2036 830 1206 0.90
HLA-A*33:01 IC50 9 1929 387 1542 0.82
HLA-A*23:01 IC50 9 1915 410 1505 0.86
HLA-A*02:01 IC50 10 2753 1150 1603 0.79
HLA-A*03:01 IC50 10 1694 720 974 0.67
HLA-A*11:01 IC50 10 1680 755 925 0.79
HLA-A*68:01 IC50 10 1651 740 911 0.73
HLA-A*31:01 IC50 10 1640 576 1064 0.65
HLA-A*02:06 IC50 10 1623 679 944 0.52
HLA-A*68:02 IC50 10 1617 481 1136 0.68
HLA-A*02:03 IC50 10 1614 811 803 0.51
HLA-A*33:01 IC50 10 1560 315 1245 0.48
HLA-A*02:02 IC50 10 1445 658 787 0.73
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1027079, 1026941, 1027588, HLA-A*02-01 binary 9 491 165 3261028928, 1029824, 1026840
1026891, 1026840 HLA-A*24-02 binary 9 378 65 313
1026840 HLA-A*30-01 binary 9 349 8 341
315312 HLA-A*31-01 binary 9 10 4 6
1026840 HLA-A*68-01 binary 9 436 43 393
1028928, 1026840 HLA-B*07-02 binary 9 308 35 273
1029125 HLA-B*27-05 binary 9 21 14 7
1026897, 1026891 HLA-B*40-01 binary 9 38 14 24
1026897, 1026891, 1026840 HLA-B*58-01 binary 9 482 63 419
1026891 HLA-A*11:01 binary 9 22 19 3











1027079, 1026941, 1027588, HLA-A*02-01 binary 9 491 165 3261028928, 1029824, 1026840
1026891, 1026840 HLA-A*24-02 binary 9 378 65 313
1026840 HLA-A*30-01 binary 9 349 8 341
315312 HLA-A*31-01 binary 9 10 4 6
1026840 HLA-A*68-01 binary 9 436 43 393
1028928, 1026840 HLA-B*07-02 binary 9 308 35 273
1029125 HLA-B*27-05 binary 9 21 14 7
1026897, 1026891 HLA-B*40-01 binary 9 38 14 24
1026897, 1026891, 1026840 HLA-B*58-01 binary 9 482 63 419
1026891 HLA-A*11:01 binary 9 22 19 3
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Table 3.4 Performance of DeepMHC on binding affinity Prediction (IC50) compared to other algorithms (9-length, methods
without winning on any dataset are omitted)
MHC allele Measure type DeepMHC NetMHCpan SMM ANN ARB IEDBConsensus NetMHCcons PickPocket
AUC SRCC Pearson AUC SRCC Pearson AUC SRCC Pearson AUC SRCC Pearson AUC SRCC Pearson - - - AUC SRCC Pearson AUC SRCC Pearson
HLA-A*02:01 IC50 0.73 0.60 0.21 0.71 0.56 0.2 0.69 0.52 0.14 0.7 0.53 0.2 0.69 0.51 0.18 - - - - - - - - -
HLA-A*02:01 t1/2 0.82 0.58 0.23 0.81 0.56 0.16 0.81 0.55 0.07 0.8 0.56 0.18 0.8 0.56 0.05 0.73 0.60 -0.01 - - - - - -
HLA-A*02:02 IC50 0.73 0.66 -0.03 0.71 0.59 -0.03 0.7 0.55 -0.01 0.74 0.65 -0.04 0.74 0.5 -0.01 0.66 0.52 0.40 0.75 0.63 -0.04 0.71 0.52 -0.02
HLA-A*02:03 IC50 0.66 0.49 0.62 0.69 0.54 0.46 0.66 0.51 0.26 0.66 0.51 0.39 0.69 0.5 0.13 0.76 0.64 0.30 0.69 0.54 0.43 0.76 0.48 0.28
HLA-A*02:06 IC50 0.79 0.69 0.37 0.78 0.65 0.21 0.75 0.62 0.11 0.77 0.64 0.2 0.74 0.6 0.24 - - - 0.79 0.67 0.2 0.74 0.51 0.35
HLA-A*24:02 IC50 0.68 0.37 0.73 0.60 0.21 0.64 0.74 0.4 0.71 0.59 0.21 0.58 0.44 0.05 0.85 - - - - - - - - -
HLA-B*35:01 IC50 0.80 0.4 0.30 0.68 0.36 0.26 0.59 0.21 0.27 0.57 0.27 0.26 0.64 0.26 0.25 - - - - - - - - -
HLA-B*58:01 IC50 0.56 0.17 0.02 0.72 0.36 0.07 0.67 0.32 0.06 0.65 0.27 0.08 0.55 0.21 0.01 - - - - - - - - -
HLA-B*58:01 t1/2 0.69 0.31 0.05 0.55 0.16 0.12 0.61 0.15 0.11 0.63 0.22 0.16 0.59 0.18 0.06 - - - - - - - - -
HLA-A*68:01 IC50 0.75 0.60 0.08 0.84 0.63 0.10 0.79 0.62 0.03 0.84 0.65 0.18 0.77 0.53 0.14 - - - - - - - - -
HLA-A*68:01 t1/2 0.23 -0.50 -0.48 0.32 -0.32 -0.33 0.25 -0.42 -0.45 0.27 -0.41 -0.37 0.31 -0.39 -0.29 - - - - - - - - -
HLA-A*68:02 IC50 0.89 0.63 0.46 0.82 0.54 0.47 0.82 0.53 0.39 0.84 0.56 0.43 0.77 0.43 0.32 0.53 0.45 0.84 0.84 0.55 0.45 0.83 0.49 0.24
HLA-B*07:02 IC50 0.88 0.66 0.52 0.8 0.71 0.63 0.86 0.74 0.38 0.89 0.77 0.73 0.77 0.69 0.41 - - - - - - - - -
HLA-B*07:02 t1/2 0.94 0.78 0.56 0.95 0.86 0.45 0.96 0.79 0.4 0.96 0.84 0.42 0.78 0.53 0.27 - - - - - - - - -
HLA-B*57:01 IC50 0.75 0.33 0.37 0.82 0.5 0.4 0.73 0.26 0.34 0.85 0.4 0.35 0.59 0.1 0.38 - - - - - - - - -
Count Of Best 6 7 6 3 5 2 2 1 0 4 2 4 0 0 1 0 0 1 2 1 0 1 0 0
Avgerage 0.73 0.45 0.27 0.72 0.46 0.25 0.71 0.42 0.16 0.72 0.45 0.24 0.66 0.35 0.19 - - - - - - - - -
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Table 3.5 Prediction Performance of DeepMHC on the binding affinity (IC50) problems against other algorithms (10-length,
Omitted some methods having no best reults)
MHC allele Measure type DeepMHC NetMHCpan SMM SMMPMBEC IEDBCconsensus
AUC SRCC Pearson AUC SRCC Pearson AUC SRCC Pearson AUC SRCC Pearson AUC SRCC Pearson
HLA-A*02-01 t1/2 0.76 0.4 0.07 0.57 0.15 -0.13 0.56 0.14 -0.10 - - - - - -
HLA-A*02-01 IC50 0.69 0.58 0.09 0.68 0.46 0.09 0.66 0.50 0.16 0.62 0.5 0.15 0.66 0.50 0.09
HLA-A*02-03 IC50 0.80 0.39 -0.05 0.75 0.25 -0.06 0.73 0.32 0.00 0.7 0.31 -0.01 0.73 0.30 0.02
HLA-A*02-06 IC50 0.82 0.66 0.14 0.81 0.64 0.15 0.83 0.64 0.21 0.84 0.66 0.22 - - -
HLA-A*68-02 IC50 0.94 0.78 0.51 0.66 0.31 0.12 0.75 0.41 0.13 0.73 0.38 0.11 0.73 0.40 0.25
Count Of Best 4 5 1 0 0 0 0 0 1 1 1 1 0 0 0
Avgerage 0.80 0.56 0.15 0.69 0.36 0.04 0.71 0.40 0.08 - - - - - -
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Table 3.6 Prediction Performance of DeepMHC on binary peptide binding
prediction
MHC allele DeepMHC NetMHCpan SMM ANN
AUC SRCC Pearson AUC SRCC Pearson AUC SRCC Pearson AUC SRCC Pearson
HLA-A*02-01 0.87 0.60 0.59 0.89 0.63 0.66 0.88 0.62 0.14 0.88 0.61 0.64
HLA-A*11-01 0.63 0.16 0.53 0.58 0.09 0.49 0.60 0.11 0.37 0.61 0.14 0.4
HLA-A*24-02 0.81 0.41 0.24 0.89 0.51 0.63 0.87 0.48 0.23 0.89 0.51 0.65
HLA-A*30-01 0.89 0.20 0.15 0.80 0.16 0.16 0.79 0.15 0.06 0.77 0.14 0.17
HLA-A*31-01 0.88 0.64 0.55 0.92 0.71 0.74 0.92 0.71 0.34 0.92 0.71 0.7
HLA-A*68-01 0.85 0.36 0.27 0.87 0.38 0.47 0.86 0.37 0.11 0.87 0.38 0.52
HLA-B*07-02 0.90 0.44 0.42 0.92 0.46 0.57 0.93 0.47 0.09 0.93 0.47 0.71
HLA-B*27-05 0.88 0.62 0.70 0.96 0.75 0.79 0.91 0.67 0.69 0.94 0.72 0.78
HLA-B*40-01 0.89 0.65 0.35 0.89 0.66 0.42 0.88 0.63 0.26 0.88 0.64 0.48
HLA-B*58-01 0.89 0.45 0.39 0.88 0.44 0.53 0.89 0.45 0.08 0.87 0.44 0.59
Count of Best 4 3 1 6 6 2 3 3 0 1 1 6
Avgerage 0.85 0.45 0.42 0.86 0.48 0.55 0.85 0.47 0.24 0.86 0.48 0.56
Table 3.7 Prediction Performance of DeepMHC V.S. HONN on BLIND Dataset
(AUC scores)
Allele DeepMHC HONN Allele DeepMHC HONN
A*01:01-BLIND 0.89 0.89 A*30:01-BLIND 0.91 0.91
A*02:01-BLIND 0.92 0.92 A*30:02-BLIND 0.72 0.78
A*02:02-BLIND 0.90 0.86 A*31:01-BLIND 0.86 0.88
A*02:03-BLIND 0.96 0.96 A*33:01-BLIND 0.91 0.91
A*02:06-BLIND 0.87 0.87 A*68:01-BLIND 0.92 0.92
A*03:01-BLIND 0.89 0.92 A*68:02-BLIND 0.96 0.95
A*11:01-BLIND 0.94 0.94 A*69:01-BLIND 0.93 0.92
A*23:01-BLIND 0.85 0.86 B*07:02-BLIND 0.90 0.88
A*24:02-BLIND 0.79 0.81 B*08:01-BLIND 0.95 0.94
A*26:01-BLIND 0.92 0.92 B*15:01-BLIND 0.90 0.92
A*29:02-BLIND 0.86 0.89 B*27:05-BLIND 0.91 0.91
B*44:02-BLIND 0.84 0.91 B*35:01-BLIND 0.86 0.85
B*51:01-BLIND 0.92 0.92 B*39:01-BLIND 0.95 0.96
B*57:01-BLIND 0.95 0.95 B*40:01-BLIND 0.93 0.93
B*58:01-BLIND 0.96 0.96
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Table 3.8 Prediction Performance of DeepMHC V.S. JHU Proposed CNN model
Allele Measure Type JHU-CNN DeepMHCAUC SRCC Pearson AUC SRCC Pearson
HLA-A*02:01 IC50 0.75 0.66 0.28 0.73 0.60 0.21
HLA-A*02:01 binary 0.80 0.49 0.49 0.87 0.60 0.59
HLA-A*02:01 t1/2 0.73 0.46 0.27 0.82 0.58 0.23
HLA-A*02:02 IC50 0.75 0.69 -0.04 0.73 0.66 0.03
HLA-A*02:03 IC50 0.68 0.54 0.70 0.66 0.49 0.62
HLA-A*02:06 IC50 0.86 0.77 0.42 0.79 0.69 0.37
HLA-A*24:02 IC50 0.58 0.32 0.43 0.68 0.37 0.73
HLA-A*24:02 Binary 0.75 0.32 0.38 0.81 0.41 0.24
HLA-A*68:01 IC50 0.58 0.22 0.14 0.75 0.60 0.08
HLA-A*68:01 Binary 0.74 0.25 0.26 0.85 0.36 0.27
HLA-A*68:01 t1/2 0.34 -0.39 -0.33 0.23 0.50 0.48
HLA-A*68:02 IC50 0.92 0.77 0.61 0.89 0.63 0.46
HLA-B*07:02 IC50 0.75 0.47 0.51 0.88 0.66 0.52
HLA-B*07:02 Binary 0.84 0.37 0.45 0.90 0.44 0.42
HLA-B*07:02 t1/2 0.78 0.51 0.39 0.94 0.78 0.56
HLA-B*35:01 IC50 0.65 0.29 0.20 0.80 0.40 0.30
HLA-B*57:01 IC50 0.66 0.27 0.25 0.75 0.33 0.37
HLA-B*58:01 IC50 0.66 0.34 0.32 0.56 0.17 0.02
HLA-B*57:01 Binary 0.82 0.37 0.40 0.89 0.45 0.39
HLA-B*58:01 t1/2 0.70 0.37 0.29 0.69 0.31 0.05
Table 3.9 Prediction Performance of DeepMHC V.S. HLA-CNN
Allele Measure Type Peptide Length Peptide Count DeepMHC HLA-CNNAUC SRCC AUC SRCC
HLA-B*57:01 IC50 9 26 0.82 0.65 0.81 0.44
HLA-A*68:02 IC50 9 55 0.88 0.62 0.99 0.72
HLA-A*02:06 IC50 9 55 0.78 0.68 0.82 0.58
HLA-A*02:03 IC50 9 55 0.66 0.48 0.75 0.37
HLA-A*02:01 IC50 9 55 0.57 0.62 0.68 0.58
HLA-A*02:01 IC50 10 35 0.66 0.56 0.59 0.33
HLA-A*02:03 IC50 10 35 0.80 0.35 0.84 0.31
HLA-A*02:06 IC50 10 35 0.81 0.60 0.92 0.64
HLA-A*68:02 IC50 10 35 0.92 0.74 0.99 0.72
Average 0.77 0.59 0.82 0.52
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Chapter 4




In Chapter 3, we introduced an allele-specific CNN-based model on the prediction of
peptide-HLA Class I binding. As discussed in Section 3.4 of last chapter, a major
con of allele-specific methods is that they could not be trained and be used to predict
on HLA alleles with few or zero samples since the peptide is the only input. Due to
the high polymorphism of HLA genes, as March 2018, there are more than 17,000
HLA alleles deposited in the IMGT/HLA database [81]. For many HLA alleles,
there are actually only a few or no experimentally determined binding affinity data
available. In contrast, a pan-specific method takes a pair of HLA allele and its binding
peptide as an input. In this way, binding pairs across all alleles can be integrated
as one training dataset. To achieve this goal, besides encoding the peptide, the
peptide-HLA binding context should also be represented in a proper way such that
the chosen machine learning model could utilize all pairs of binding samples. The
key idea behind pan-specific models is that besides encoding the peptide in a proper
way for the prediction model, the peptide-HLA binding context/environment is also
represented so that the machine learning models could be trained on all available
peptide-HLA binding samples [110]. In Figure 4.1, we show the difference between
allele-specific methods and pan-specific methods.
In this chapter, we will first discuss the existing pan-specific models and their
limitations in section 4.2. Then our proposed method is presented in section 4.3. We
test our model on benchmark dataset and compare the results with other methods in
section 4.4.
4.2 Related work
As of now, a number of pan-specific models have been proposed for both HLA class
I and class II alleles [110]. Pseudo-sequence based methods are currently most suc-
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Figure 4.1 Illustration of difference between allele-specific framework and
pan-specific framework. Left panel show the allele-specific framework where for each
allele, a model needs to be trained on available peptides. In the right panel, a
pan-specific model could takes into binding complex of all alleles together and a
universal model will be obtained.
cessful ones with high performance when trained on a large amount of HLA class I
binding affinity data. NetMHCPan [26] is the first pan-specific binding affinity pre-
diction algorithm that trains on a large number of peptide-HLA binding samples of
different HLA alleles. It proposed the pseudo sequence encoding method to represent
the binding context, in which an HLA sequence is reduced to a pseudo amino acid
sequence of length 34 based on a representative set of HLA structures with nonamer
peptides. Each amino acid in this pseudo sequence is selected if it is in contact with
the peptide within 4.0
◦
A (0.4 nm). The extracted interaction map is shown in Figure
4.2. this extracted 34-length pseudo sequence is a fixed list of location indexes of
amino acids. For any given HLA allele’s sequence, the corresponding 34 residues are
extracted and used to represent this HLA allele. In NetMHCPan, a HLA-peptide
binding sample is represented as a 43-length residue sequence: 9 from peptide and 34
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from HLA. This sequence is then encoded in three different ways: one-hot encoding,
BLOSUM50 and a mixture of both. The encoded input is then used to train multiple
feed forward neural networks with 22 to 86 hidden neurons. Then the network with
the highest prediction performance (lowest square error) on the test set was selected
as the final prediction model [26]. NetMHCPan later has been improved several times
by training with additional training data. The latest version is NetMHCPan 4.0 [36].
This pseudo sequence encoding approach has also been used in PickPocket [108]
and Kim’s algorithm [23], but the two methods use different machine learning algo-
rithms for model training. In PickPocket, position-specific scoring matrices (PSSMs)
are first derived from peptides data. Then extract the position-specific vectors from
the PSSMs in association with pseudo-sequence to construct a pocket library. Each
pocket library entry is characterized by nine pairs, where each pair consists of a list
of pocket amino acids and a specificity vector. Kim et al. proposed a pan-specific
DCNN model for peptide-MHC class I binding prediction, in which pseudo sequence
encoding is adopted for HLA sequences and the DCNN model is setup as a 26-layer
classifier [23].
The pseudo sequence encoding is currently the dominating binding context en-
coding method in pan-specific peptide-HLA class I binding prediction. This encoding
method has its potential limitations: 1) its interaction map extraction step relies
on available MHC-peptide bound complex structures,which can not cover all alle-
les, especially considering the high polymorphism of HLA proteins; 2) the 34 contact
residues of the encoding is empirical and only covers part of the whole HLA sequence.
In next section, we propose DeepSeqPan, a deep neural network trained on pairs of
one-hot encoded raw peptides and HLA sequences. Our method does not require 3-D
structural data during training stage and it could obtain state-of-the-art performance
on standard benchmark.
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Figure 4.2 Interaction map of the HLA pseudo sequence in NetMHCPan.
Reproduced from original paper.
4.3 Method
4.3.1 Dataset
We use same training dataset BD2013 from IEDB as we did for DeepMHC. All
training samples are labeled with IC50 binding affinity values. The testing dataset is
downloaded from IEDB’s weekly benchmark dataset ranging from 2014-03-21 to 2018-
01-26 (http://tools.iedb.org/auto_bench/mhci/weekly). To address the concern that
duplicate peptides may exist in both the training and testing data downloaded from
IEDB, we removed all duplicate peptides from the testing dataset. The alignment-
ready HLA sequences were obtained from IMGT/HLA database [81]. We trained
our model on 9-length peptides binding to HLA-A, HLA-B and HLA-C alleles with
available HLA sequences. Totally, the training dataset contains 121,787 peptide-
HLA binding peptides covering 42 HLA-A alleles (72618 samples), 49 HLA-B alleles
(46915 samples) and 10 HLA-C alleles (2254 samples). The detailed information of
the training dataset are listed in Table 3.1
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4.3.2 Sequence Encoding
In this model, we use one-hot encoding for both peptide and HLA sequences. A
9-length peptide sequence is encoded into a 2D tensor with dimension 1 × 9 × 20
where the last dimension is the number of channels and each channel represents one
of 20 amino acids. Figure 4.3 illustrates the encoded peptide HLNPNKTKR as a
2D tensor with dimension 1× 9× 20. Since HLA class I sequences downloaded from
IMGT/HLA database have variable lengths, we chose the maximum length 372 as
the fixed dimension. Then we encode each aligned HLA sequence into a 2D tensor
with dimension 1 × 372 × 21. The extra channel represents gaps in HLA sequences
shorter than 372.
H L N P N K T K R
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
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Figure 4.3 Peptide encoding example. Sequence HLNPNKTKR is encoded into a
2D tensor with dimension 1 (height) × 9 (width) × 20 (channel). Each of 20
channels represents one amino acid type and we set a channel value to 1 if the
corresponding amino acid appears at this location of the input sequence.
4.3.3 DeepSeqPan
Architecture. As shown in Figure 4.4, the DeepSeqPan network consists of three
parts:
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(i) Peptide encoder and HLA encoder. The peptide and HLA encoders con-
vert a pair of one-hot encoded peptide and HLA sequences into two tensors
with a unified dimension 1 × 9 × 10. The output tensors of two encoders are
concatenated along the channel axis to generate an encoded feature tensor with
dimension 1 × 9 × 20. Then this concatenated tensor will be fed into the bind-
ing context extractor in (ii). The purpose of these two encoders is extracting
high-level features from raw sequences and encoding them into a feature tensor.
Different from the 34 pseudo amino acid sequence encoding approach in [26],
the features and information stored inside this feature tensor are learned by the
deep neural network automatically with its end-to-end training framework. The
encoder of the peptide consists of two blocks of convolutional, batch normaliza-
tion and LeakyReLu layers. As for the HLA encoder whose input sequence is
much longer than the peptide, we used a network configuration similar to the
VGG network [89].
(ii) Binding context extractor. The extractor takes into the encoded feature
tensor from (i) and outputs a 2560-dimension vector. This vector is actually
the binding context between a peptide and a HLA. This binding context ex-
tractor will be optimized automatically in the training stage through the back-
propagation algorithm and the extraction of the binding context is done by the
network itself without human involvement. Especially, in this extractor we use
Locally Connected layers (as illustrated LCBlock in Figure 4.4) instead of stan-
dard convolutional layers with weights sharing. The reason is that the encoded
high-level features in the feature tensor is position related, i.e. in the encoded
feature tensor with length 9, an extracted feature A located at position 1 should
have different effect as it appears at position 7. Locally connected layers have
the capability to capture features at specific locations since its filters at differ-
ent locations do not share weights, which has been proved to be powerful in
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DeepFace [93].
(iii) Affinity predictor and binding probability predictor. Another novel de-
sign of DeepSeqPan is that at the output layer, both the binding probabilities
and the IC50 value are used as output in final stage (iii). This is different
from all other DCNN based MHC binding prediction algorithms[23, 99] which
outputs either the binding probabilities or IC50 values. This design is not a
captain’s call. Actually, at first when we were training the DeepSeqPan that
only predicts IC50 values, we found it was very hard to train the network with
very slow convergence. So we added the binding probability predictor as an
additional source of supervision signal with the expectation that the backprop-
agation algorithm can train the network easier by taking advantage of two types
of losses: the classification loss and regression loss. Note that we can calculate
the binary binding probability for the training samples from their IC50 binding
affinity values via Equation (4.4). The underlying relationship between regres-
sion outputs and classification outputs is built up naturally. In the training
stage, the network needs to learn this underlying relationship in order to re-
duce the total loss. In that case, we argue that the classification predictor plays
as a regularizer by forcing the network to predict a more accurate IC50 values.
Layer configuration details. In Figure 4.4, there are several layers we need to give
more details:
• FC N : A fully connected layer with N hidden units.
• Dropout: We used 0.5 as the dropout rate.
• ConvBlock N : A ConvBlock N consists of 4 layers in following order:
1. A 2D convolutional layer with N filters of size 1× 3
2. A Batch normalization layer
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3. A 2D convolutional layer with N filters of size 1× 3
4. A Max pooling with kernel size 1× 2
• LCBlock N : A LCBlock N consists of 3 layers in following order:
1. A 2D Locally Connected layer with N filters of size 1× 2
2. A Batch normalization layer
3. A LeakyReLU activation layer
Loss function. The overall loss L is the sum of the regression loss LR and the
classification loss LC as illustrated in Equation (4.1).
L = LR + LC (4.1)
For IC50 predictor, we use mean squared error (MSE, Equation (4.2)) as the loss











′)− (1− P )log(1− P ′) (4.3)
To get binary binding labels, we use standard 500 nM threshold to convert a IC50
value label into a binding label:
P =

1, if IC50< 500.
0, otherwise.
(4.4)
Training. We randomly split all training samples into a training set and a valida-
tion set following 4:1 ratio. Stochastic gradient descent (SGD) is employed as the
optimization algorithm enabled with momentum and learning rate decay. The ini-
tial learning rate is 0.001 and the momentum factor is 0.8. It is scheduled to halve
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the learning rate if validation loss hasn’t improved within 5 epochs. The minimum
learning rate is set to 0.00001. The training process stops if the validation loss has
not improved within 15 epochs. We used Keras [14] deep learning framework to

























































Figure 4.4 DeepSeqPan Network Structure. (i) Peptide and HLA encoders. (ii)
Binding context extractor. (iii) Affinity and binding predictors.
4.3.4 Metrics and label processing
Area under the curve (AUC) and Spearman’s rank correlation coefficient (SRCC) are
used as evaluation metrics to compare with the public benchmark results at IEDB
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website [96]. In pan-specific binding prediction modeling, the IC50 values of the
peptides span a large range [0, 80000]. To avoid gradient explosion issue in neural
network training, we convert IC50 to logIC50 via Equation 4.5. The logIC50 are then
used as labels during training. During inference stage, we convert the prediction
results back to IC50 values.
logIC50 = logeIC50 (4.5)
4.4 Experiments and results
4.4.1 Cross-validation on the training dataset
Standard five-fold cross-validation experiments are applied over the training dataset.
Since our network outputs both IC50 affinity values and binding probabilities, we
evaluated the performances on both outputs separately. We use AUC and SRCC
discussed in section 4.3.4 to measure the performance.
In table 4.1, All rows show the 5-fold cross-validation results of our algorithm
on the original training dataset. When the calculated the metrics on all samples,
DeepSeqPan achieved a high AUC of 0.94 for regression on IC50 and an AUC of
0.94 for binary binding classification. The corresponding SRCC is 0.73 (IC50) and
0.70 (binary binding) respectively. When evaluated over the samples of HLA-A, -B
and -C alleles separately, all the AUC scores are around or above 0.90 and all the
SRCC scores are above 0.60. More comprehensive metrics evaluated on each allele
are reported in Table 4.2. In this table, some AUC scores are N/A because of that in
training dataset, there are few alleles coming with 0 positive samples. Thus, it is not
applicable to compute AUC score. Also, we can find that some SRCC scores are also
N/A in Table 4.2. These happen if the number of an allele’s samples is < 2. It is not
applicable to calculate SRCC score without at least 2 data points. For allele HLA-
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A*02:10, the Spearmanr function gives N/A result because all samples are labeled as
same values which is also a non-calculable situation.
Besides performing cross validation on the original training dataset, we also did
a cross validation on a CD-HIT [52] filtered training dataset. The reason behind this
is that in the original training dataset, some peptides have high similarities. When
do cross validation on the original training dataset, these similar peptides may lead
to over estimating of our model’s performance. CD-HIT is a widely used tool to
cluster protein sequences based on their alignment similarities. We first use it to
group all peptides in our training dataset with sequence identity threshold 0.7, i.e.
if two peptides have similaritiy > 0.7, they will be clustered into on group. After
this step, 20,148 unique peptide sequences are grouped into 14,812 clusters. Then for
each cluster, we only keep peptide with the greatest number of samples. In this way,
we got a new training dataset for cross-validation, we name it training-cd-hit. Then
we did the normal 5-fold cross-validation on this training set. In Table 4.2, we listed
the performance of model trained on this filtered dataset (CD-HIT filtered rows). As
shown in the table, AUC scores are much better than model trained on all dataset
with all achieved 1.0. SRCC scores are slightly worse than the model trained on all
dataset. We can see that our model keeps the performance on the training-cd-hit
dataset.
4.4.2 Evaluation on benchmark dataset
To evaluate how our DeepSeqPan performs compared to other HLA-peptide binding
prediction algorithms, we applied it to the public IEDB weekly benchmark dataset
upon which a set of top algorithms have been evaluated with published results.
We trained a single DeepSeqPan model on all 9-length peptides in the training
dataset that bind to HLA-A, -B and -C alleles. Then this trained model was evaluated
on all available IEDB weekly benchmark dataset [96]. As we inform before, the IEDB
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benchmark dataset has been filtered by removing duplicate samples. We compared
the performance of DeepSeqPan with those of pan-specific models: NetMHCPan (2.8)
[25], NetMHCPan (3.0) [68] and PickPocket [108], the performances of allele-specific
models: SMM [76], NetMHC (3.4) [59], NetMHC (4.0) [2], ARB [12], MHCflurry [73]
and AMMPMBEC [96], and those of ensemble models (results are based on several
different models): IEDB Consensus [96] and NetMHCcons [38]. Metrics of compared
models are listed in Table 4.6. This table summarizes the performance of different
algorithms on 64 testing datasets from IEDB benchmark database. For each dataset,
we highlighted the highest AUC scores in yellow and highest SRCC scores in pink
and then counted the number of datasets upon which each algorithm achieved the
highest scores and put them at the last row of the table. We found that DeepSeqPan
achieved the highest AUC scores in 19 records out of total 64 testing records. In 45
records that DeepSeqPan didn’t achieve the highest AUC scores, there are 28 records
on which the AUC scores of DeepSeqPan are very close to the highest AUC scores
within a small margin around 0.1. In terms of SRCC, DeepSeqPan obtained the
highest scores on 13 records.
From Table 4.6, it can be found that different pan-specific and allele-specific meth-
ods have the best performance on datasets of various alleles, which implies the good
performance of the ensemble methods such as NetMHCcons since they make predic-
tion via combining results from multiple methods [96]. Our proposed DeepSeqPan
could thus be a complementary tool for existing pan-specific models and it is promis-
ing to include it into the state-of-the-art ensemble prediction models to improve their
performance.
4.4.3 Comparison with other DCNN models
To the best of our knowledge, Kim et lt.’s work [15] is the only pan-specific model
that employs DCNN architecture beside our proposed DeepSeqPan. It uses NetMHC-
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Pan’s pseudo sequence encoding for binding context modeling, in which a pair of
peptide-HLA binding sample is encoded into a 9 (height) × 34 (width) × 18 (chan-
nel) 2D tensor. Each "pixel" in this 2D tensor represents a contacting pair of a
peptide reside and a HLA residue. For two contacting residues, 9 physicochemi-
cal properties are used for each one and in total 18 values are encoded in chan-
nels. Their network structure is VGG-like and consists of 26 layers. They trained
their model with binding samples on HLA-A and HLA-B alleles and it used the
same dataset BD2013 as we did. To compare the performance of our DeepSeqPan
with Kim’s method, we evaluated the benchmark dataset with their online server
(http://jumong.kaist.ac.kr:8080/convmhc) on all its supporting alleles (HLA-A and
HLAB alleles). In total, we evaluated 54 benchmark datasets on Kim’s server and
compared with ours obtained in previous benchmark evaluation and the binary pre-
diction outputs were used to compare. Since Kim’s model was trained as a classifier,
we calculated AUC scores for each testing dataset and in Table 2 we showed the aver-
age AUC scores measured based on all HLA-A or HLA-B testing dataset respectively
(Detailed performance on each dataset is listed in Supplementary Files). Out of all
54 benchmark datasets, Kim’s model and our model both got an average AUC of
0.76. For HLA-A datasets, two model also obtained same average AUC of 0.74. Our
model slightly out performed Kim’s model on HLA-B alleles with an average AUC of
0.80. Overall, two models achieved similar performance and in terms of performance
on each allele as shown in Table 4.3, two models obtained better performances on
different sets of HLA alleles and none can dominate the other model.
4.4.4 Generalization of DeepSeqPan to binding predictions of new HLA
alleles
One major advantage of pan-specific models over allele-specific models for HLA-
peptide binding prediction is that it can make predictions on HLA alleles that are not
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included in the training dataset. This is especially useful for HLA alleles without any
samples with known binding affinity values. In order to evaluate this extrapolation
capability of DeepSeqPan, we setup a 3-fold blind cross validation. We first grouped
all alleles into 3 groups: HLA-A, -B and -C. In this blind test, each of 3 models were
trained on 2 groups of alleles and then tested on another group of alleles. We call
those trained model Blind models since they didn’t see any alleles from testing. All
samples are taken from the CD-HIT training dataset such that we can compare these
3 model’s performances with that of 5-fold cross-validation. The CD-HIT training
dataset was obtained from previous cross-validation experiment.
The comparison results are shown in Table 4.4. The columns under 3-fold blind
test are performance results of the Blind models. Columns under 5-fold cross val-
idations are results obtained from previous 5-fold crossvalidation on same training
dataset. Overall, the blind models perform worse than 5-fold cross validation as ex-
pected since in both 3 folds, the training datasets are much smaller comparing with
that of 5-fold cross validations. For example, when tested on HLA-A group alleles,
the model was trained on 43,462 samples while it was tested on 60,987 samples. The
number of testing samples is even larger than the number of training samples. Same
situations for HLA-B and HLA-C groups. However, as shown in Table 4.4, thereâĂŹre
several records in groups B and C where blind model achieved better or similar per-
formance (HLA-B*15:42, HLA-B*27:02, HLAB*42:02, HLA-B*45:06, HLA-B*52:01,
HLA-B*57:03, HLA-B*58:02 and HLA-C*04:01). We think this happened because
when the network trained on A-B dataset or A-C dataset, it could learned the basic
cross allele features with a number of samples (102,347 of A-B, 63,088 of A-C) even
only fed with raw sequences.
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4.4.5 The binding context vector: consistency and capability
One of key design features of our DeepSeqPan model (Figure 4.4 (ii)) is the binding
context vector aiming to capture high-level features that determine whether a peptide
and a HLA bind or not and if so, how strong the binding is. Another key feature
of our model is the dual outputs of the model: the binding affinity output and the
binary binding probability output.
Since the binding context vector is used as input for both predicted outputs, it
should be consistent for both the IC50 predictor and the binary binding predictor in
(iii): for the same binding context vector, both predictors should give consistent out-
puts. In other words, higher binding probability should correspond to higher binding
affinity values. To verify this consistency, we inspected IC50 and binary prediction
outputs of all samples from previous cross-validation and benchmark evaluation ex-
periments. The analysis results are shown in Table 4.5. First row of the table lists the
numbers of evaluated samples in the cross-validation and benchmark evaluation ex-
periments with 121,787 in cross-validation and 19,741 in benchmark evaluation. The
second row shows the number of consistent outputs. Given a sample pair of peptide
and HLA, we marked its predicted IC50 value and the predicted binding probability
as consistent if both values indicate binding or not binding. An IC50 value of < 500
or a binding probability of 0.5 or greater indicates the binding state. From the table
we can observe that high consistency exists between the regression and classification
outputs. For cross-validation experiments, the percentage of consistent outputs is
95.81% and for benchmark evaluation experiments, this percentage is 86.14%.
In last two rows of Table 4.5, we reported the number of correct predictions mea-
sured with the IC50 predictions and the binary prediction respectively. A predicted
IC50 value or a predicted binary binding probability value is marked as a correct
prediction if its real label and the prediction value indicate the same binding state:
binding or not binding. Given a sample, it will be marked as binding if its IC50 value
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is less than the threshold (500 nM). If the sample binding affinity is labelled with t1/2
type, measured minutes less than 120 indicates the binding state For binary binding
labels, a binary label of 1 means it is binding while a value of 0 means no binding. For
the predicted binary binding probability, a probability value of > 0.5 means binding.
From Table 4.5, we found that both affinity and binary binding outputs obtained
accuracies greater than 88% in cross-validation experiments. In benchmark experi-
ments, the accuracy rate is 59% for IC50 predictions and binary predictions have an
accuracy of 53%. The results showed that the consistency between IC50 predictions
and binary predictions is high, which means that the binding context vector extracted
by DeepSeqPan contains common effective features for determining binding states.
In Figure 4.5 we plotted the correlation between binary values and regression
values predicted on benchmark dataset. Each dot in this plot represents a testing
sampleâĂŹs two prediction values by DeepSeqPan. The x axis value is the predicted
logIC50 and the y axis value is the predicted binary binding probability. The Pearson
correlation value calculated is -0.97. We also fitted a linear function into these corre-
lation data and the fitted linear function is y = −0.1x+1.0. From the figure, it shows
that two output values have very strong correlation when both indicate very strong
binding or very weak binding (upper left part and lower right part). It displays weak
correlation when the two predicted values indicate the binding is neither strong or
weak.
Though the results show that the two output values have a pretty strong cor-
relation overall. There are some cases they will give contradicting predictions. We
think the major reason behind this is that in the training dataset, thereâĂŹre some
edge samples. Following the 500 nM hard convention value, for samples whose IC50
values are slightly above 500 (e.g. 502.03), their binary labels will be 0. And for
those samples whose IC50 values are slightly below 500 (e.g. 498.33), their binary
labels will be 1. After training, when the model does prediction on those similar
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edge samples in testing dataset, the predicted regression values and binary labels are
easy to contradict to each other. It can be seen that around hard convention line
(x = 6.20) in Figure 4.5, the correlation is almost weakest. In practical usage, users
should be careful on predicted regression values around 500 and measure the result
based on two outputs. But if users only care strong binding samples, according to
our correlation analysis on benchmark testing, the two values show strong correlation
in strong binding cases. That will not be a problem.
Figure 4.5 Correlation analysis between binary prediction values and regression
prediction values on benchmark dataset.
4.5 Chapter summary
In this chapter, we proposed, DeepSeqPan, a novel deep convolutional neural net-
work model for pan-specific HLA-peptide binding affinity prediction. This model is
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characterized by its capability of binding prediction with only the raw amino acid
sequences of the peptide and the HLA, which makes it applicable to HLA-peptide
binding prediction for HLA alleles without structural information. This is achieved
by a novel sequence-based encoding of the peptide-HLA binding context, a binding
context feature extractor, and the dual outputs with both binding affinity and binding
probability predictions. Extensive evaluation of DeepSeqPan on public benchmark
experiments showed that our model achieves state-of-the-art performance on a variety
of HLA allele datasets.
Our model contributes to the study of MHC-peptide binding prediction in a few
special ways. First, our experiments showed that it is possible to extrapolate the bind-
ing prediction capability to unseen HLA alleles, which is important for pan-specific
models. Second, our sequence-only based binding context encoding is complementary
to the pseudo sequence encoding, which is currently the only encoding method used
in pan-specific models for class I MHC-peptide binding affinity prediction. This has
the potential to further improve the state-of-the-art prediction models such as the
pan-specific model NetMHCSpan. It showed the importance of sufficient amount of
training data to achieve high prediction performance for deep learning models. More-
over, our proposed sequence-based DCNN architecture for protein-peptide binding is
universal and can be adapted to other similar binding problems such as protein-DNA,
protein-RNA and protein-ligand/drug bindings.
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Table 4.1 Cross validation results on original training data (All) and CD-HIT
filtered training data (CD-HIT filtered)
TrainingDataset Alleles Seq Count
IC50 Binary Binding
AUC SRCC AUC SRCC
All
All alleles 121,787 0.94 0.73 0.94 0.70
HLA-A 72,618 0.94 0.75 0.94 0.73
HLA-B 46,915 0.94 0.68 0.94 0.64
HLA-C 2,254 0.89 0.70 0.89 0.69
CD-HIT filtered
All alleles 104,449 1.00 0.71 1.00 0.68
HLA-A 60,987 1.00 0.73 1.00 0.71
HLA-B 41,360 1.00 0.66 1.00 0.62
HLA-C 2,102 1.00 0.69 1.00 0.68
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AUC SRCC AUC SRCC AUC SRCC AUC SRCC
A*01:01 0.93 0.57 0.94 0.55 B*15:09 0.88 0.47 0.89 0.47
A*02:01 0.95 0.81 0.95 0.81 B*15:17 0.93 0.69 0.94 0.69
A*02:02 0.93 0.86 0.93 0.86 B*15:42 0.82 0.04 0.65 -0.01
A*02:03 0.95 0.82 0.95 0.82 B*18:01 0.90 0.52 0.89 0.48
A*02:04 N/A N/A N/A N/A B*27:01 0.00 -1.00 0.00 -1.00
A*02:05 0.99 0.84 0.98 0.81 B*27:02 N/A -0.50 N/A -0.50
A*02:06 0.91 0.80 0.91 0.79 B*27:03 N/A 0.03 N/A -0.01
A*02:07 0.76 0.75 0.79 0.79 B*27:04 N/A 1.00 N/A 1.00
A*02:10 N/A N/A N/A N/A B*27:05 0.94 0.63 0.94 0.59
A*02:11 0.96 0.80 0.96 0.80 B*27:06 N/A -1.00 N/A -1.00
A*02:12 0.97 0.77 0.97 0.77 B*27:10 N/A N/A N/A N/A
A*02:16 0.98 0.68 0.98 0.68 B*27:20 0.56 0.52 0.54 0.56
A*02:17 0.68 0.41 0.69 0.41 B*35:01 0.90 0.72 0.91 0.71
A*02:19 0.96 0.66 0.96 0.66 B*35:03 0.87 0.50 0.90 0.54
A*02:50 1.00 0.88 0.99 0.87 B*37:01 0.48 0.01 0.61 0.13
A*03:01 0.93 0.73 0.93 0.72 B*38:01 0.98 0.81 0.98 0.80
A*03:02 0.69 0.57 0.68 0.57 B*39:01 0.93 0.62 0.93 0.61
A*03:19 0.87 0.55 0.87 0.56 B*40:01 0.97 0.63 0.97 0.59
A*11:01 0.95 0.77 0.95 0.76 B*40:02 0.90 0.76 0.90 0.75
A*11:02 1.00 0.77 1.00 0.77 B*40:13 0.64 0.48 0.61 0.46
A*23:01 0.93 0.71 0.92 0.68 B*42:01 0.94 0.77 0.94 0.77
A*24:02 0.90 0.67 0.90 0.66 B*42:02 0.84 0.64 0.82 0.63
A*24:03 0.96 0.70 0.96 0.68 B*44:02 0.95 0.60 0.94 0.55
A*25:01 0.98 0.47 0.99 0.47 B*44:03 0.94 0.82 0.95 0.82
A*26:01 0.93 0.52 0.93 0.49 B*45:01 0.92 0.67 0.91 0.66
A*26:02 0.96 0.74 0.96 0.74 B*45:06 0.81 0.14 0.71 0.17
A*26:03 0.93 0.52 0.94 0.54 B*46:01 0.92 0.44 0.93 0.44
A*29:02 0.88 0.65 0.87 0.63 B*48:01 0.92 0.49 0.92 0.50
A*30:01 0.91 0.70 0.92 0.70 B*51:01 0.92 0.58 0.92 0.55
A*30:02 0.82 0.63 0.82 0.62 B*52:01 0.58 0.29 0.50 0.18
A*31:01 0.93 0.74 0.93 0.74 B*53:01 0.92 0.78 0.93 0.77
A*32:01 0.85 0.71 0.85 0.72 B*54:01 0.90 0.73 0.90 0.73
A*32:07 0.81 0.53 0.82 0.53 B*57:01 0.96 0.62 0.96 0.59
A*32:15 0.51 0.38 0.50 0.36 B*57:02 0.84 0.66 0.80 0.62
A*33:01 0.92 0.73 0.92 0.73 B*57:03 0.97 0.74 0.97 0.75
A*66:01 0.83 0.41 0.84 0.35 B*58:01 0.95 0.69 0.96 0.68
A*68:01 0.90 0.79 0.90 0.79 B*58:02 0.55 0.51 0.59 0.55
A*68:02 0.92 0.70 0.92 0.69 B*73:01 0.64 0.36 0.66 0.37
A*68:23 0.77 0.53 0.78 0.54 B*81:01 0.92 0.76 0.93 0.76
A*69:01 0.94 0.51 0.94 0.53 B*83:01 0.93 0.53 0.93 0.53
A*74:01 0.70 0.45 0.61 0.33 C*03:03 0.80 0.59 0.79 0.58
A*80:01 0.94 0.55 0.95 0.55 C*04:01 0.52 -0.09 0.58 -0.15
B*07:02 0.95 0.72 0.95 0.72 C*05:01 0.91 0.74 0.92 0.75
B*08:01 0.91 0.66 0.91 0.65 C*06:02 0.89 0.74 0.89 0.74
B*08:02 0.96 0.42 0.96 0.44 C*07:01 0.84 0.61 0.84 0.61
B*08:03 0.92 0.35 0.95 0.38 C*07:02 0.74 0.42 0.73 0.41
B*14:01 0.74 0.43 0.74 0.44 C*08:02 0.64 0.28 0.63 0.25
B*14:02 0.84 0.51 0.85 0.43 C*12:03 0.62 0.28 0.61 0.29
B*15:01 0.90 0.67 0.90 0.67 C*14:02 0.67 0.28 0.67 0.29
B*15:02 0.77 0.53 0.77 0.53 C*15:02 0.79 0.52 0.80 0.55
B*15:03 0.90 0.75 0.90 0.75
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Table 4.3 Evaluation results of Kim’s DCNN and DeepSeqPan
MHC IEDB Ref Measure Type Count
AUC
Kim DeepSeqPan (Binary)
A*01-01 1028282 t1/2 6 1.00 1.00
A*02-01 1026371 t1/2 34 0.70 0.76
A*02-01 1026840 Binary 341 0.85 0.85
A*02-01 1026840 IC50 22 0.79 0.55
A*02-01 1026840 t1/2 22 0.69 0.58
A*02-01 1027079 Binary 15 0.80 0.80
A*02-01 1027471 Binary 43 0.79 0.88
A*02-01 1027588 Binary 18 0.70 0.82
A*02-01 1028285 t1/2 135 0.75 0.72
A*02-01 1028553 IC50 22 0.85 0.95
A*02-01 1028554 IC50 44 0.75 0.91
A*02-01 1028928 Binary 11 0.92 0.94
A*02-01 1029824 Binary 77 0.59 0.58
A*03-01 1028288 t1/2 221 0.84 0.85
A*03-01 1031253 IC50 14 0.96 1.00
A*11-01 1026891 Binary 16 0.71 0.67
A*11-01 1028287 t1/2 219 0.79 0.76
A*24-02 1026840 Binary 346 0.84 0.83
A*24-02 1026840 IC50 19 0.62 0.61
A*24-02 1026891 Binary 19 0.55 0.68
A*24-02 1028289 t1/2 423 0.73 0.74
A*30-01 1026840 Binary 347 0.87 0.85
A*30-02 1026840 Binary 360 0.73 0.72
A*30-02 1026840 IC50 56 0.51 0.55
A*30-02 1026840 t1/2 56 0.48 0.49
A*31-01 315312 Binary 8 0.94 0.88
A*66-01 315312 Binary 16 0.39 0.14
A*68-01 1026840 Binary 436 0.86 0.84
A*68-01 1026840 IC50 35 0.84 0.78
A*68-01 1026840 t1/2 35 0.42 0.33
B*07-02 1026371 t1/2 33 0.89 0.91
B*07-02 1026840 Binary 288 0.86 0.81
B*07-02 1028291 t1/2 136 0.82 0.82
B*07-02 1028553 IC50 22 0.84 0.90
B*07-02 1028554 IC50 52 0.80 0.80
B*07-02 1028928 Binary 11 1.00 1.00
B*07-02 1031253 IC50 13 1.00 1.00
B*15-01 1028293 t1/2 570 0.74 0.62
B*15-02 1027131 Binary 14 1.00 1.00
B*27-05 1029125 Binary 21 0.97 0.95
B*27-05 1031253 IC50 12 0.60 0.63
B*35-01 1028292 t1/2 363 0.81 0.74
B*35-01 1028554 IC50 56 0.47 0.58
B*40-01 1026891 Binary 19 0.83 0.81
B*40-01 1026897 Binary 15 0.80 0.80
B*44-03 1028554 IC50 46 0.54 0.80
B*57-01 1028554 IC50 53 0.87 0.89
B*57-01 1029061 IC50 17 0.90 0.95
B*58-01 1026840 Binary 433 0.87 0.85
B*58-01 1026840 IC50 34 0.77 0.53
B*58-01 1026840 t1/2 34 0.44 0.58
B*58-01 1026891 Binary 20 0.66 0.67
B*58-01 1026897 Binary 22 0.81 0.90
B*27-05 1031959 Binary 13540 0.60 0.60
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Table 4.4 Comparision results of 3-fold blind testing and 5-fold corss validations
on each alleles in trainign data with CD-HIT filtered. Highlited cells are higher
scores in that record.
Allele
5-fold cross validation 3-fold blind test
Allele
5-fold cross validation 3-fold blind test
IC50 AUC IC50 AUC IC50 AUC IC50 AUC
AUC SRCC AUC SRCC AUC SRCC AUC SRCC AUC SRCC AUC SRCC AUC SRCC AUC SRCC
A*01:01 1.00 0.57 1.00 0.55 0.55 0.13 0.55 0.10 B*15:09 1.00 0.47 0.99 0.49 0.37 -0.11 0.37 -0.10
A*02:01 1.00 0.81 1.00 0.80 0.68 0.35 0.72 0.41 B*15:17 1.00 0.69 1.00 0.69 0.73 0.38 0.73 0.39
A*02:02 1.00 0.85 1.00 0.85 0.71 0.43 0.72 0.46 B*15:42 1.00 0.06 1.00 0.00 0.59 0.00 0.60 0.01
A*02:03 1.00 0.80 1.00 0.79 0.69 0.35 0.71 0.40 B*18:01 1.00 0.50 1.00 0.46 0.45 0.05 0.44 0.01
A*02:04 - - - - - - - - B*27:01 - - - - - - - -
A*02:05 1.00 0.85 1.00 0.81 0.79 0.47 0.86 0.55 B*27:02 1.00 0.60 1.00 0.60 - 0.80 - 0.80
A*02:06 1.00 0.79 1.00 0.77 0.67 0.34 0.70 0.40 B*27:03 1.00 -0.05 1.00 -0.01 - -0.01 - -0.01
A*02:07 1.00 0.79 1.00 0.81 0.73 0.08 0.77 0.17 B*27:04 1.00 1.00 1.00 1.00 - -0.50 - -0.50
A*02:10 - - - - - - - - B*27:05 1.00 0.60 1.00 0.57 0.55 0.12 0.50 0.06
A*02:11 1.00 0.80 1.00 0.80 0.65 0.26 0.69 0.32 B*27:06 - 1.00 - 1.00 - -1.00 - -1.00
A*02:12 1.00 0.77 1.00 0.77 0.67 0.24 0.71 0.31 B*27:10 - - - - - - - -
A*02:16 1.00 0.68 1.00 0.69 0.60 0.11 0.65 0.17 B*27:20 1.00 0.50 1.00 0.47 0.36 -0.19 0.38 -0.29
A*02:17 1.00 0.38 1.00 0.38 0.61 0.26 0.61 0.27 B*35:01 1.00 0.69 1.00 0.68 0.58 0.13 0.60 0.16
A*02:19 1.00 0.65 1.00 0.65 0.65 0.20 0.68 0.22 B*35:03 1.00 0.50 1.00 0.54 0.48 -0.15 0.51 -0.10
A*02:50 1.00 0.86 1.00 0.87 0.44 -0.05 0.44 -0.06 B*37:01 1.00 0.37 1.00 0.25 0.53 -0.02 0.53 0.06
A*03:01 1.00 0.72 1.00 0.71 0.45 -0.08 0.42 -0.13 B*38:01 1.00 0.59 1.00 0.59 0.20 -0.29 0.24 -0.27
A*03:02 1.00 0.54 1.00 0.53 0.61 0.44 0.67 0.40 B*39:01 1.00 0.62 1.00 0.62 0.42 -0.09 0.42 -0.10
A*03:19 1.00 0.20 1.00 0.23 0.57 0.13 0.52 0.10 B*40:01 1.00 0.59 1.00 0.55 0.40 -0.03 0.40 -0.05
A*11:01 1.00 0.77 1.00 0.75 0.43 -0.09 0.42 -0.14 B*40:02 1.00 0.73 1.00 0.69 0.54 0.04 0.53 0.02
A*11:02 1.00 0.79 0.96 0.94 0.52 0.13 0.33 -0.19 B*40:13 1.00 0.56 1.00 0.56 0.44 -0.07 0.43 -0.10
A*23:01 1.00 0.68 1.00 0.64 0.60 0.21 0.61 0.22 B*42:01 1.00 0.83 1.00 0.83 0.41 -0.20 0.38 -0.21
A*24:02 1.00 0.67 1.00 0.66 0.61 0.20 0.62 0.21 B*42:02 1.00 0.43 1.00 0.41 0.97 0.48 0.91 0.35
A*24:03 1.00 0.67 1.00 0.65 0.67 0.29 0.68 0.30 B*44:02 1.00 0.56 1.00 0.51 0.36 0.02 0.37 0.01
A*25:01 1.00 0.48 1.00 0.48 0.58 0.10 0.62 0.14 B*44:03 1.00 0.79 0.99 0.79 0.45 -0.03 0.43 -0.06
A*26:01 1.00 0.50 1.00 0.47 0.64 0.19 0.66 0.18 B*45:01 1.00 0.65 0.99 0.63 0.49 -0.06 0.47 -0.09
A*26:02 1.00 0.76 1.00 0.75 0.61 0.20 0.62 0.20 B*45:06 1.00 0.09 1.00 0.08 0.45 0.09 0.43 0.09
A*26:03 1.00 0.52 1.00 0.53 0.64 0.18 0.66 0.20 B*46:01 1.00 0.41 1.00 0.42 0.74 0.21 0.75 0.21
A*29:02 1.00 0.62 1.00 0.59 0.54 0.11 0.54 0.10 B*48:01 1.00 0.54 1.00 0.54 0.57 0.06 0.60 0.10
A*30:01 1.00 0.67 1.00 0.67 0.50 0.06 0.51 0.07 B*51:01 1.00 0.54 1.00 0.51 0.52 0.05 0.53 0.05
A*30:02 1.00 0.64 0.99 0.62 0.51 0.04 0.51 0.02 B*52:01 1.00 0.36 1.00 0.04 0.67 0.07 0.75 0.29
A*31:01 1.00 0.73 1.00 0.73 0.45 -0.09 0.45 -0.08 B*53:01 1.00 0.70 1.00 0.70 0.47 0.03 0.49 0.05
A*32:01 1.00 0.67 1.00 0.68 0.72 0.43 0.72 0.43 B*54:01 1.00 0.70 1.00 0.69 0.52 -0.04 0.52 -0.03
A*32:07 1.00 0.33 1.00 0.31 0.38 -0.08 0.41 -0.03 B*57:01 1.00 0.59 1.00 0.56 0.77 0.35 0.78 0.35
A*32:15 1.00 0.27 1.00 0.24 0.71 0.26 0.71 0.24 B*57:02 1.00 0.84 1.00 0.82 0.67 0.64 0.67 0.65
A*33:01 1.00 0.71 0.99 0.71 0.36 -0.18 0.38 -0.18 B*57:03 1.00 0.46 1.00 0.40 0.64 0.51 0.61 0.49
A*66:01 1.00 0.42 1.00 0.39 0.46 0.10 0.50 0.10 B*58:01 1.00 0.64 1.00 0.63 0.70 0.34 0.71 0.34
A*68:01 1.00 0.78 1.00 0.77 0.43 -0.15 0.43 -0.19 B*58:02 1.00 0.43 0.98 0.47 0.86 0.50 0.85 0.48
A*68:02 1.00 0.66 1.00 0.66 0.66 0.27 0.67 0.29 B*73:01 1.00 0.51 1.00 0.48 0.54 0.05 0.55 0.12
A*68:23 1.00 0.54 1.00 0.54 0.49 -0.07 0.49 -0.07 B*81:01 1.00 0.81 1.00 0.78 0.37 0.03 0.43 0.15
A*69:01 1.00 0.50 1.00 0.51 0.69 0.22 0.73 0.27 B*83:01 1.00 0.55 1.00 0.55 0.37 -0.18 0.39 -0.15
A*74:01 1.00 0.68 1.00 0.68 0.46 0.07 0.54 0.20 C*03:03 1.00 0.60 0.99 0.58 0.42 -0.10 0.43 -0.09
A*80:01 1.00 0.57 1.00 0.57 0.49 -0.06 0.50 -0.05 C*04:01 - -0.06 - -0.10 0.58 0.10 0.57 0.10
B*07:02 1.00 0.71 1.00 0.71 0.42 -0.08 0.42 -0.08 C*05:01 1.00 0.75 1.00 0.74 0.50 0.00 0.52 0.03
B*08:01 1.00 0.66 1.00 0.65 0.47 -0.02 0.47 -0.02 C*06:02 1.00 0.67 1.00 0.67 0.63 0.21 0.64 0.21
B*08:02 1.00 0.47 1.00 0.48 0.47 -0.07 0.49 -0.06 C*07:01 1.00 0.65 1.00 0.65 0.39 -0.29 0.39 -0.29
B*08:03 1.00 0.37 1.00 0.39 0.56 0.04 0.61 0.07 C*07:02 1.00 0.51 0.99 0.46 0.38 -0.15 0.38 -0.16
B*14:01 1.00 0.30 1.00 0.31 0.57 -0.13 0.55 -0.15 C*08:02 1.00 0.20 0.97 0.15 0.48 0.13 0.47 0.10
B*14:02 1.00 0.41 1.00 0.33 0.52 0.18 0.48 0.11 C*12:03 1.00 0.29 0.99 0.27 0.59 0.16 0.59 0.19
B*15:01 1.00 0.66 1.00 0.66 0.67 0.30 0.67 0.30 C*14:02 1.00 0.09 0.99 0.07 0.43 -0.02 0.45 -0.04
B*15:02 1.00 0.56 1.00 0.55 0.66 0.30 0.67 0.34 C*15:02 1.00 0.50 1.00 0.49 0.29 -0.42 0.28 -0.43
B*15:03 1.00 0.69 1.00 0.69 0.66 0.21 0.65 0.19
Table 4.5 Consistency inspection results
Cross Validation Benchmark Evaluation
Total samples 121787 19741
Consistent pred. 116688 (95.81%) 17004 (86.14%)
Correct IC50 pred. 108064 (88.73%) 11690 (59.21%)
Correct Binary pred. 107239 (88.05%) 10487 (53.12%)
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Table 4.6 Evaluation on benchmark database. Red/Yellow highlighted number(s) are best AUC/SRCC scores in that record.
Sorted by IEDB Ref ID.
HLA Type
Pan-specific Allele-specific Ensemble
DeepSeqPan NetMHCpan 2.8 NetMHCpan 3.0 PickPocket SMM NetMHC 3.4 NetMHC 4.0 ARB SMMPMBEC MHCflurry IEDB Consensus NetMHCcons
AUC SRCC AUC SRCC AUC SRCC AUC SRCC AUC SRCC AUC SRCC AUC SRCC AUC SRCC AUC SRCC AUC SRCC AUC SRCC AUC SRCC
B*27-03 Binary 0.58 0.14 0.92 0.71 - - 0.88 0.64 - - - - - - - - - - - - - - 0.92 0.71
A*66-01 Binary 0.11 -0.45 - - 0.54 0.04 0.68 0.20 0.68 0.20 - - 0.25 -0.29 - - 1.00 0.57 0.86 0.41 0.64 0.16 0.61 0.12
A*31-01 Binary 0.88 0.65 - - 0.88 0.65 0.88 0.65 0.88 0.65 - - 0.88 0.65 - - 0.88 0.65 0.88 0.65 0.88 0.65 0.88 0.65
B*07-02 t1/2 0.93 0.66 0.93 0.81 - - - - 0.93 0.72 0.93 0.77 - - 0.72 0.44 - - - - - - - -
A*02-01 t1/2 0.75 0.41 0.75 0.42 - - - - 0.77 0.45 0.76 0.45 - - 0.75 0.45 - - - - - - - -
B*07-02 Binary 0.83 0.29 0.87 0.32 - - - - 0.88 0.33 0.88 0.33 - - 0.85 0.31 - - - - - - - -
C*07-01 Binary 0.67 0.15 0.78 0.25 - - - - 0.65 0.13 0.76 0.23 - - - - - - - - - - - -
C*07-01 IC50 0.32 -0.29 0.54 -0.18 - - - - 0.39 -0.01 0.61 0.17 - - - - - - - - - - - -
A*30-01 Binary 0.83 0.17 0.81 0.16 - - - - 0.79 0.15 0.77 0.14 - - 0.71 0.11 - - - - - - - -
B*58-01 Binary 0.84 0.36 0.86 0.38 - - - - 0.87 0.40 0.85 0.37 - - 0.84 0.36 - - - - - - - -
B*58-01 IC50 0.52 0.19 0.72 0.38 - - - - 0.70 0.38 0.68 0.33 - - 0.57 0.26 - - - - - - - -
B*58-01 t1/2 0.56 0.03 0.54 0.15 - - - - 0.53 0.08 0.54 0.16 - - 0.50 0.12 - - - - - - - -
A*30-02 Binary 0.72 0.35 0.77 0.42 - - - - 0.73 0.36 0.75 0.40 - - 0.65 0.25 - - - - - - - -
A*30-02 IC50 0.64 0.21 0.47 0.01 - - - - 0.54 0.12 0.59 0.13 - - 0.64 0.27 - - - - - - - -
A*30-02 t1/2 0.43 0.15 0.50 0.05 - - - - 0.50 0.07 0.55 0.19 - - 0.52 0.15 - - - - - - - -
A*68-01 Binary 0.82 0.33 0.87 0.38 - - - - 0.86 0.37 0.87 0.38 - - 0.78 0.34 - - - - - - - -
A*68-01 IC50 0.76 0.44 0.84 0.63 - - - - 0.79 0.62 0.84 0.65 - - 0.77 0.53 - - - - - - - -
A*68-01 t1/2 0.40 -0.13 0.32 -0.32 - - - - 0.25 -0.42 0.27 -0.41 - - 0.31 -0.39 - - - - - - - -
A*24-02 Binary 0.81 0.34 0.85 0.39 - - - - 0.82 0.36 0.85 0.38 - - 0.83 0.37 - - - - - - - -
A*24-02 IC50 0.54 0.16 0.63 0.18 - - - - 0.76 0.39 0.61 0.19 - - 0.45 0.03 - - - - - - - -
A*02-01 Binary 0.82 0.42 0.89 0.52 - - - - 0.88 0.51 0.87 0.49 - - 0.88 0.51 - - - - - - - -
A*02-01 IC50 0.69 0.31 0.72 0.36 - - - - 0.68 0.37 0.63 0.29 - - 0.74 0.45 - - - - - - - -
A*02-01 t1/2 0.74 0.33 0.73 0.43 - - - - 0.74 0.37 0.67 0.29 - - 0.69 0.46 - - - - - - - -
C*07-02 Binary 0.60 0.17 0.65 0.25 - - - - 0.74 0.39 0.75 0.41 - - - - - - - - - - - -
A*11-01 Binary 0.21 -0.33 0.43 -0.08 - - - - 0.50 0.00 0.46 -0.04 - - 0.14 -0.41 - - - - - - - -
B*58-01 Binary 0.59 0.16 0.88 0.64 - - - - 0.76 0.44 0.88 0.64 - - 0.84 0.58 - - - - - - - -
B*40-01 Binary 0.81 0.54 0.92 0.73 - - - - 0.86 0.62 0.91 0.71 - - 0.87 0.64 - - - - - - - -
A*24-02 Binary 0.50 0.00 0.63 0.19 - - - - 0.57 0.09 0.53 0.05 - - 0.55 0.07 - - - - - - - -
B*58-01 Binary 0.77 0.32 0.74 0.28 - - - - 0.81 0.37 0.75 0.30 - - 0.67 0.20 - - - - - - - -
B*40-01 Binary 0.82 0.49 0.75 0.38 - - - - 0.84 0.52 0.75 0.38 - - 0.75 0.38 - - - - - - - -
A*02-01 Binary 0.77 0.46 0.77 0.46 - - - - 0.68 0.31 0.75 0.43 - - 0.68 0.31 - - - - - - - -
B*15-02 Binary 1.00 0.71 1.00 0.71 - - 1.00 0.71 0.91 0.58 1.00 0.71 - - 1.00 0.72 1.00 0.71 1.00 0.71 1.00 0.71 1.00 0.71
A*02-01 Binary 0.94 0.49 0.84 0.38 - - - - 0.83 0.36 0.81 0.34 - - 0.81 0.35 - - - - - - - -
A*02-01 Binary 0.87 0.63 0.83 0.56 - - - - 0.84 0.58 0.82 0.55 - - 0.75 0.43 - - - - - - - -
C*03-03 IC50 1.00 0.77 0.68 0.68 - - 0.64 0.47 0.68 0.46 0.68 0.46 - - - - 0.76 0.67 - - 0.68 0.46 0.68 0.56
A*01-01 t1/2 1.00 0.84 1.00 0.90 - - 1.00 0.90 1.00 0.81 1.00 0.90 - - 1.00 0.75 1.00 0.90 - - 1.00 0.79 1.00 0.90
A*02-01 t1/2 0.78 0.49 0.76 0.52 - - 0.82 0.59 0.79 0.56 0.74 0.51 - - 0.79 0.49 0.78 0.55 - - 0.78 0.56 0.76 0.53
A*11-01 t1/2 0.80 0.58 0.90 0.76 - - 0.80 0.51 0.90 0.75 0.90 0.74 - - 0.87 0.67 0.90 0.75 - - 0.91 0.76 0.91 0.76
A*03-01 t1/2 0.81 0.50 0.85 0.58 - - 0.77 0.48 0.86 0.56 0.85 0.57 - - 0.85 0.54 0.86 0.57 - - 0.86 0.58 0.86 0.59
A*24-02 t1/2 0.74 0.48 0.79 0.56 - - 0.81 0.60 0.80 0.57 0.78 0.57 - - 0.76 0.50 0.80 0.58 - - 0.80 0.59 0.80 0.60
A*26-01 t1/2 - -0.5 - -0.5 - - - 0.50 - 0.50 - -0.5 - - - 0.50 - 0.50 - - - 0.50 - -0.50
B*07-02 t1/2 0.83 0.67 0.89 0.78 - - 0.81 0.69 0.88 0.76 0.87 0.76 - - 0.80 0.63 0.88 0.76 - - 0.88 0.76 0.89 0.78
B*35-01 t1/2 0.79 0.52 0.83 0.62 - - 0.83 0.60 0.81 0.58 0.83 0.62 - - 0.74 0.45 0.81 0.58 - - 0.82 0.59 0.84 0.64
B*15-01 t1/2 0.59 0.19 0.74 0.43 - - 0.61 0.22 0.71 0.40 - - - - 0.59 0.20 0.71 0.40 - - 0.70 0.38 0.74 0.43
B*40-01 t1/2 - 0.98 - 0.96 - - - 0.93 - 0.86 - 0.98 - - - 0.73 - 0.93 - - - - - 0.98
B*07-02 IC50 0.89 0.81 0.89 0.66 - - 0.89 0.62 0.89 0.62 0.92 0.76 - - 0.88 0.55 0.88 0.62 - - 0.92 0.72 0.91 0.72
A*02-01 IC50 0.88 0.52 0.92 0.62 - - 0.83 0.58 0.85 0.59 0.91 0.70 - - 0.90 0.69 0.83 0.62 - - 0.84 0.62 0.92 0.64
B*07-02 IC50 0.71 0.61 0.77 0.62 - - 0.74 0.70 0.85 0.66 0.88 0.70 - - 0.76 0.65 0.86 0.70 - - 0.88 0.70 0.86 0.73
B*57-01 IC50 0.80 0.43 0.86 0.62 - - 0.85 0.44 0.77 0.33 0.94 0.52 - - 0.63 0.12 0.77 0.29 - - 0.87 0.43 0.92 0.56
B*35-01 IC50 0.64 0.20 0.68 0.36 - - 0.50 0.28 0.59 0.21 0.57 0.27 - - 0.64 0.26 0.53 0.20 - - 0.65 0.30 0.64 0.36
B*44-03 IC50 0.77 0.31 0.61 0.46 - - 0.64 0.43 0.75 0.47 0.65 0.56 - - 0.56 0.25 0.76 0.55 - - 0.64 0.51 0.64 0.55
A*02-01 IC50 0.75 0.44 0.89 0.70 - - 0.88 0.51 0.89 0.58 0.82 0.62 - - 0.76 0.51 0.86 0.55 - - 0.84 0.58 0.89 0.69
B*07-02 Binary 1.00 0.50 1.00 0.50 - - 1.00 0.50 1.00 0.50 1.00 0.50 - - 1.00 0.50 1.00 0.50 - - 1.00 0.52 1.00 0.50
A*02-01 Binary 1.00 0.67 0.94 0.60 - - 0.92 0.56 0.94 0.60 0.94 0.60 - - 0.94 0.60 0.94 0.60 - - 0.94 0.60 0.94 0.60
B*57-01 IC50 0.83 0.63 0.88 0.60 - - 0.86 0.72 0.88 0.64 0.81 0.64 - - 0.40 0.12 0.81 0.65 0.90 0.67 0.83 0.64 0.83 0.57
B*27-04 Binary 0.89 0.63 0.94 0.72 - - 0.83 0.53 - - - - - - - - - - - - - - 0.94 0.72
B*27-06 Binary 0.75 0.42 0.75 0.42 - - 0.80 0.50 - - - - - - - - - - - - - - 0.75 0.42
B*27-05 Binary 0.89 0.63 0.96 0.75 - - 0.91 0.67 0.91 0.67 0.94 0.72 - - 0.88 0.62 0.96 0.75 0.89 0.63 0.91 0.68 0.96 0.75
A*02-01 Binary 0.55 0.07 0.55 0.07 - - 0.55 0.08 0.57 0.10 0.57 0.11 - - 0.52 0.04 0.57 0.10 0.57 0.11 0.57 0.11 0.56 0.09
B*38-01 IC50 - -0.70 - 0.00 - - - -0.10 - -0.10 - -0.10 - - - -0.50 - -0.10 - 0.30 - -0.10 - 0.00
B*07-02 IC50 1.00 0.93 - - 1.00 0.97 1.00 0.87 1.00 0.96 - - 1.00 0.98 - - 1.00 0.97 1.00 0.91 1.00 0.97 1.00 0.97
A*03-01 IC50 0.93 0.87 - - 0.93 0.78 0.96 0.71 0.87 0.69 - - 0.96 0.79 - - 0.91 0.75 0.76 0.56 0.91 0.74 0.91 0.76
B*27-05 IC50 0.77 0.67 - - 0.63 0.59 0.60 0.49 0.63 0.44 - - 0.69 0.58 - - 0.60 0.46 0.57 0.48 0.63 0.49 0.66 0.62
B*27-05 Binary 0.60 0.16 - - 0.60 0.16 0.60 0.16 - - - - - - - - - - - - - - 0.60 0.16
Highlighted 19 13 23 19 3 2 10 7 16 10 16 14 3 2 4 6 8 5 5 3 10 5 16 15
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Chapter 5
Attention-like LSTM-CNN network on




As we introduced before, besides HLA class I, another import subgroup of HLA is
HLA class II. The HLA class II are also heterodimers, like HLA class I. But in class
II, both α and β chains are encoded by HLA genes and are interaction with binding
peptides. Figure 5.1 illustrates the structure of HLA class II. The α1 and β1 regions of
the chains come together to make a membrane-distal peptide-binding domain [103].
The peptide binding groove, is made up of two α-helixes walls and β-sheet [34]. Since
the binding groove of HLA class II is open at both ends (while class I is closed at
both ends), the peptides binding to HLA class II are longer, between 15 and 24 amino
acid residues long [53].
Figure 5.1 Schematic representation of HLA class II. Reproduced from wikipedia
Comparing with HLA class I, there are much less methods proposed on peptide-
HLA class II binding prediction, both allele-specific and pan-specific. And the per-
formance of those models are considerably inferior to that of HLA class I methods
[4]. There are several reasons make the class II prediction model more challenging:
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• The peptides binding to HLA class II are longer and thus have more dynamic
lengths. This requires models have a capability to encode variant lengths input
sequences.
• In HLA class I, an HLA allele has only one protein sequence and different alleles
have same lengths. But in class II, an HLA allele has two protein sequences
and each sequence may have very variant length.
• As we know the peptides binding to HLA class II are much longer. However,
only a small part (usually 9-length amino acid residues, called binding core) of it
will be fitted into the binding groove [110]. Given a peptide, researchers are also
interested in the binding core prediction besides affinity prediction. Currently,
only few methods offer identification of the binding core given a peptide.
In this chapter, we propose an attention LSTM model addressing on the peptide-
HLA class II binding prediction problem. Our model is a pan-specific model which
could give both affinity prediction and binding core prediction. In Section 5.2, we
first introduce related works in this area. In next Section 5.2, we give the details of
our proposed model. We compare our method on benchmark dataset and show the
result in Section 5.4. Finally, we summarize our work in Section 5.5.
5.2 Related work
Like prediction models in HLA class I, existing models on class II binding prediction
can be grouped into either allele-specific or pan-specific. NN-align [69], TEPITOPE
[91], ARB [12], SVRMHC [100] and MHCpred [21] are some allele-specific meth-
ods. As for pan-specific methods, TEPITOPEpan [109] and NetMHCIIpan [70] are
currently available models.
ARB, as a quantitative statistical method, uses a derived Average Relative Binding
(ARB) matrix that directly predict IC50 values allowing combination of searches
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involving different peptide sizes and alleles into a single global prediction. In ARB,
the author assumes individual side chains of a peptide’s amino acids contribute to
binding independently. If a residue r appears at position i in a peptide, it’s assumed
to contribute a constant amount of Ei,r to the free energy of binding of this peptide.
Ei,r was estimated as:
Ei,r = 10(Pi,r−Qi,r) (5.1)
where Pi,r is the geometric average binding affinity of peptides containing residue r
at position i and Qi,r is the geometric average binding affinity (IC50) of the remaining
peptides [12]. Given a training dataset, an ARB matrix could be derived. With this





In above equation. L is the length of this peptide.
In SVRMHC, the author developed a support vector machine regression (SVR)
model to predict binding affinities. For peptide sequence encoding, user tried one-hot
encoding and 11-dimension feature vector introduced in [54]. On exploring different
configuration combinations of SVR kernels and encoding method, it chose the best
performance model as the final model [100].
MHCpred introduced a partial least square (PLS) based additive model. An
additive model assumes that the binding affinity of a peptide could be presented as a
sum of the contributions of the amino acids at each position and certain interactions
between them [21]. In MHCpred, each peptide was represented by a binary bit string
of 180 bins (9 positions × 20 amino acids). One-hot encoding was used to encode each
amino acid of a peptide. After construction of the matrix, an iterative self-consistent
PLS-based algorithm was used to fit a scoring function.
A vanilla feed-forward artificial neural network was introduced in NN-align. It
could give predictions of both binding cores and binding affinities. In NN-align,
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each peptide was encoded with Blosum matrix. During training, a peptide will be
processed to generate all possible 9-length subsequences. The core of a given peptide
was identified as the highest scoring of all 9 mers contained within the peptide. Given
a binding core, the weights were updated to lower the sum of squared errors between
the predicted binding score and the measured binding affinity target value [69]. An
ensemble method was employee by NN-align in which a group of neural networks
with 2, 10, 20, 40 and 60 hidden neurons was built. And for each type of network,
10 duplicates with different starting weights were trained. In total, 50 networks were
created. The author chose 10 networks with highest performance to assemble the final
prediction model. The binding core of a given peptide was assigned by a majority
vote of the networks in the ensemble [69].
TEPITOPEpan is a pan-specific method which utilized position-specific weight
matrix (PSSM) and 3D structure to compute the binding affinities. It first gener-
ated pseudo sequences of all HLA-DR alleles based on 32 structures of HLA-peptide
complexes. For each complex, it extracted the contacting residue positions on HLA
alleles. Totally, 45 residue positions were extracted to represent an HLA allele. Then
the pocket similarity and weight between any two alleles’ pseudo sequences were cal-
culated via method introduced in [108]. Finally, given any pair of a peptide and an
HLA allele, the binding affinities was estimated via a weighted summary based on 11
available alleles’ PSSMs [109].
Another pan-specific model, NetMHCIIpan also used pseudo sequence method to
encode HLA alleles. Similar to TEPITOPEpan, the pseudo sequence were extracted
from a series of 3D complexes. In NetMHCIIpan, the author extracted 34 amino acid
residue locations to represent an allele: 15 from the α-chain and 19 from β-chain. The
input sequences were encoded with three methods:(i) one-hot encoding, (ii) Blosum
encoding, and (iii) a mixture of two. A group of networks with 22, 44, 56 and 66
hidden units were trained and the binding affinity were scored as the average of all
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networks [70]. NetMHCIIpan preprocessed all peptides with alignment matrix and
assigned each nonamer a normalized binding affinity. In this way, it could predict the
binding core given a long peptide.
In this chapter, we propose a pan-specific model which only requires raw inputs of
peptides and HLA alleles sequences. With the help of attention LSTM, each peptide-
HLA sample only needs to be fed into the network one time to predict both affinity
and binding core. In next section, we give the details of our proposed model.
5.3 Method
5.3.1 Attention LSTM
Initial long short-term memory (LSTM) model was proposed by Hochreiter and
Schmidhuber [24]. The LSTM has been found extremely successful in many areas
especially in natural language process [6, 20, 19]. A simplified LSTM cell is illus-
trated in Figure 5.2. The most critical part of the cell is the state unit which has a
self-loop. By making the weight of this self-loop gated, the time scale of integration
can be changed dynamically [18]. The forward process is calculated as follow:
it = σ(Wiixt +Wifht−1 + bi) (5.3)
ft = σ(Wfixt +Wffht−1 + bf ) (5.4)
ot = σ(Woixt +Wofht−1 + bo) (5.5)
ct = ft • ct−1 + it • tanh(Wcixt +Wcfht−1 + bc) (5.6)
ht = ot • tanh(ct) (5.7)
Even LSTM show its power in many NLP problems, researchers found that using
a fixed-size representation, usually the last output of a LSTM model, to capture the
semantic information of a very long sentence is very difficult [18]. One way to solve
this problem is to train a sufficiently deep LSTM model and train it for a long time,
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Figure 5.2 Simplified illustration of a LSTM cell. Reproduced from wikipedia
which has been demonstrated in [15, 7]. In 2015, Bahdanau et al. introduced atten-
tion mechanism on machine translation problem. In original attention mechanism,
the LSTM reads the whole input first and then outputs the translated word one at
a time while each time it focusing on a different part of the input. The model was
designed such that it could automatically learn which part to focus. To achieve this
goal, several implementations have been proposed to calculation the attention weight
vector. Another benefit of attention LSTM is that by visualizing this attention weight
vector, we could have a directly feeling about which part of the input the model is
focusing on for the prediction.
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Figure 5.3 Architecture of our proposed model. (a) The overall structure. (b) The
detail illustration of the attention LSTM module. (c) Dimensions of inputs and
intermediate tensors/vectors.
5.3.2 Proposed method
We propose a attention-like LSTM model to predict the binding affinities and binding
cores of peptide-HLA class II. Since our problem is a sequence-to-value problem,
which is totally different from machine translation’s sequence-to-sequence problem.
We design a novel network architecture to calculate the peptide’s attention weight
vector from a LSTM module and output binding affinity in the final stage. The
overall architecture of our proposed model is shown in Figure 5.3.
Sequence encoding
We still use one-hot encoding as we did in Chapter 3 and Chapter 5. Figure 4.3
illustrates the one-hot encoding. A peptide or protein sequence is encoded as a
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tensor with shape: 1 × L × 20. L is the max length of HLA sequences or peptide
sequences. In our model, the max length of HLAs is 275 and that of peptides is 25.
If a sequence’s length is shorter than L, we pad 0 at the end.
Architecture
Our model consists of three modules as shown in Figure 5.3 (a):
• Encoder. A input of our model contains three parts: HLA α-chain sequence,
HLA β-chain sequence and peptide sequence. Each sequence was encoded us-
ing one-hot encoding. For each input sequence, we construct an attention-like
LSTM encoder of which the detail is shown in Figure 5.3 (b). We setup the
LSTM with 100 hidden states and behave in a bi-directional way. As shown in
the figure, we collect two outputs: the last hidden state and output values of
all amino acids residues. The output tensor has dimension L× 200 where L is
the max length of HLA chains or peptides. The last hidden state (a 200-dim
vector) is then fed into a fully connected (FC) layer with L hidden units where
L is the max length of HLA chains or peptides. After FC layer, we apply Soft-
Max activation function on this L-length vector. In this way, we could obtain
an attention weight vector with same length as input sequence and the sum of
all values equal to 1. Here, we want to point out several processing we did: (i)
we masked the all output by assigning all padding positions with 0 manually
(shown as a MASK layer after All output in Figure 5.3 (b)), (ii) the hidden state
we use was valid final hidden state, i.e. the hidden state of the last valid input
instead of padded final input, and (iii) before applying SoftMax, we mask the
output vector from FC layer by assigning all padding elements with 0 manually
(shown as a MASK layer after FC layer in Figure 5.3 (b)). An example for (ii),
if a peptide has 15 amino acids, it would be encoded as a 25 × 20 tensor. We
use the 15th hidden state as the output hidden state instead of the 25th one
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since the 15th one is the valid one. We did these processing because we want
the LSTM only focus on valid input and ignore the padding noises. After we
have the attention weight, we do a batch matrix-multiply (BMM) between all
output and attention weight. Then we can get our weighted output with size
L. For all three input sequences, after going through their encoders, we will
get three weighted output vectors with same dimension 200 and three (we only
plotted peptide’s one in the figure) attention weight vectors of which two have
dimension 273 for HLA chains and one has dimension 25 for peptide.
• Context extractor With three output vectors obtained from encoder, we first
concatenate three vectors as a tensor with dimension 200×3. Then we feed this
tensor into a CNN network consisting of two 1D convolutional layers. The first
layer is configured with 256 filters of size 3 and the second CNN layer has 64
filters of size 3. For both two layers, we use LeakyRelu [106] as the activation
function. Finally, we flatten the output of 2nd CNN layer as 25,600 dimension
vector.
• Predictor In the last stage of our model, we use two vanilla fully connected
layers to output the final IC50 value. First layer has 200 hidden units and second
one has 1 hidden unit. We place dropout layer [90] between two FC layers. For
the 2nd FC layer, we use tanh as the activation function.
Training Strategy
We fed the network with a batch of 512 samples and employed Early Stop to con-
trol the training. The samples are randomly split into training group and validation
group following 9:1 ratio. We stopped training if validation loss hasn’t improve in 5
continuous epochs. Mean squared error (MSE) was used as the loss function. For op-
timizer, we used basic stochastic gradient descent (SGD) algorithm. We implemented
our model with PyTorch Framework [75].
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5.3.3 Dataset
The training dataset is collected by [3]. This dataset contains about 130,000 train-
ing samples over 72 HLA class II alleles. The IC50 labels were normalized in the
original dataset and all of them are in a scale of 0.0 ∼ 1.0. For testing, we use
the standard weekly benchmark dataset [4] from 2016-12-31 to 2017-12-29 which can
be accessible at http://tools.iedb.org/auto_bench/mhcii/weekly/. We group
testing samples by its allele and measure type. Totally, we have 44 testing groups.
For each group, we use area under the curve (AUC) and Spearman’s rank correlation
coefficient (SRCC) as metrics by following the convention.
5.4 Experiment
5.4.1 Evaluation on standard benchmark
We trained a model following the description in Section 5.3.2. Then we tested
our model on the standard benchmark dataset which contains 44 testing groups.
The evaluation results of other methods are included in the original benchmark
dataset. We calculated AUC and SRCC for each testing group. The results are
listed in Table 5.1. Our proposed method obtained highest AUC scores in 19 testing
groups and highest SRCC scores in 17 testing groups. Another pan-specific method
NetMHCIIpan-3.1 obtained highest AUC and SRCC scores in 18 and 20 testing
groups, respectively. All other allele-specific methods and the ensemble method did
not perform good enough to compare. Specially, we found that our method performs
very well on alleles: HLA-DRA*01:01/DRB1*15:02, HLA-DRA*01:01/DRB1*13:01,
HLA-DQA1*03:03/DQB1*04:02 and HLA-DQA1*01:02/DQB1*05:01.
The results showed that our proposed method could outperform existing methods
on certain alleles. For the rest alleles, our model also could achieve competitive
performance. This benchmark testing demonstrate that the model we proposed could
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capture the complex pattern relationship between HLA chains and peptide based on
one-hot encoded information. Since two pan-specific methods outperform each other
on different alleles, it’s intuitive to ensemble these two methods in practical usage.
5.4.2 Estimate the binding core
A benefit of our proposed model could directly estimate the binding core based on
attention weight vector obtained from attention LSTM (as shown in Figure 5.3 (a)).
We use Algorithm 1 to identify the binding core from attention weight vector. Basi-
cally, we find the 9-length subsequence with maximum attention weight and we think
this subsequence is the binding core. Comparing with NetMHCIIpan which predicts
on every possible 9-length subsequence of a peptide and select the one with highest
predicted binding affinity as binding core, our model is a neat one-shot prediction.
Algorithm 1 Binding core identification algorithm




5: while i < L− 9 + 1 do
6: coreWeight← ∑ attnV ec[i : i+ 9]
7: if coreWeight > maxWeight then
8: maxWeight← coreWeight
9: core← i
10: return core . Return the starting index of predicted binding core
To verify our model’s binding core prediction capability, we tested our trained
model obtained in Section 5.4.1 on 47 HLA class II - peptide complexes structures.
These structures and observed binding cores were collected by [31]. The prediction
results are shown in Figure 5.4. For each peptide, we underscored the observed
binding core portion. The correctly predicted amino acids are green highlighted. For
false positive predicted amino acids, they are red highlighted. And false negative
predicted amino acids are blue highlighted. Of 47 records, 24 binding cores are
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correctly predicted. In 10 structures, our predicted binding cores are either right or
left offset with one amino acid. The predicted binding cores are either right or left
offset with two amino acids in 9 records. Two predicted binding cores show 3 amino
acids offset and two show 4 amino acids offset.
5.5 Summary
In this chapter, we proposed an attention-like LSTM-CNN model on class II HLA-
peptide binding prediction problem. We tested it on the benchmark dataset and
obtained state-of-the-art performance. Among 44 testing groups, we outperformed
other methods on 19 groups for AUC and 17 groups for SRCC. Also, as a sequence
based method, our method could be applied on all alleles with known sequences. With
attention mechanism, our method could directly output the binding core prediction
without feeding all possible 9-mers of a peptide. As currently the only non pseudo
sequence based pan-specific method, we successfully applied attention LSTM network
in this area and obtained one of the best performances. We argue that by ensemble
with existing method, researchers could get much better prediction results.
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Figure 5.4 Binding core prediction results on 47 HLA class II - peptide complex
structures. The observed binding core from 3D structure is underscored. For the
binding core predicted by our model, the correctly predicted amino acids are green
highlighted, the false positive amino acids are red highlighted, and the false negative
amino acids are blue highlighted.
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Table 5.1 Benchmark evaluations results. Highlighted cells are highest scores in that test group.
Allele (Alpha/Beta) Count Type
Pan specific Allele specific Ensemble
Our Method NetMHCIIpan-3.1 NN-align Comblib matrices SMM-align Tepitope (Sturniolo) Consensus IEDB
AUC SRCC AUC SRCC AUC SRCC AUC SRCC AUC SRCC AUC SRCC AUC SRCC
DQA1*01:02/DQB1*05:01 825 IC50 0.778 0.554 0.596 0.215 - - - - - - - - - -
DQA1*01:02/DQB1*06:02 10 IC50 0.438 -0.115 0.813 0.224 0.813 0.273 0.250 -0.236 1.000 0.382 - - 0.750 0.224
DQA1*01:03/DQB1*06:03 357 IC50 0.842 0.425 0.809 0.424 - - - - - - - - - -
DQA1*02:01/DQB1*03:01 818 IC50 0.777 0.532 0.814 0.588 - - - - - - - - - -
DQA1*02:01/DQB1*03:03 759 IC50 0.823 0.631 0.760 0.537 - - - - - - - - - -
DQA1*02:01/DQB1*04:02 765 IC50 0.758 0.453 0.519 0.039 - - - - - - - - - -
DQA1*03:01/DQB1*03:02 18 IC50 0.500 0.149 0.973 0.550 0.964 0.622 0.830 0.423 0.946 0.722 - - 0.991 0.702
DQA1*03:03/DQB1*04:02 567 IC50 0.692 0.299 0.482 -0.080 - - - - - - - - - -
DQA1*05:01/DQB1*03:02 834 IC50 0.803 0.582 0.771 0.574 - - - - - - - - - -
DQA1*05:01/DQB1*03:03 564 IC50 0.822 0.581 0.812 0.614 - - - - - - - - - -
DQA1*05:01/DQB1*04:02 747 IC50 0.718 0.435 0.577 0.140 - - - - - - - - - -
DQA1*06:01/DQB1*04:02 565 IC50 0.726 0.343 0.497 -0.056 - - - - - - - - - -
DRA*01:01/DRB1*01:01 69 Binary 0.809 0.479 0.837 0.521 0.833 0.515 0.661 0.248 0.786 0.443 0.229 -0.420 0.787 0.444
DRA*01:01/DRB1*01:01 1070 IC50 0.827 0.644 0.799 0.635 0.781 0.596 0.696 0.428 0.737 0.507 0.282 -0.457 0.748 0.535
DRA*01:01/DRB1*03:01 1001 IC50 0.775 0.509 0.855 0.710 0.789 0.598 - - 0.784 0.576 0.247 -0.516 0.797 0.606
DRA*01:01/DRB1*03:01 79 Binary 0.537 0.062 0.624 0.208 0.587 0.146 - - 0.618 0.196 0.432 -0.113 0.600 0.168
DRA*01:01/DRB1*04:01 104 Binary 0.640 0.242 0.763 0.455 0.770 0.466 - - 0.692 0.333 0.222 -0.481 0.694 0.336
DRA*01:01/DRB1*04:01 179 IC50 0.732 0.379 0.838 0.579 0.805 0.503 - - 0.667 0.339 0.439 -0.193 0.676 0.337
DRA*01:01/DRB1*04:04 861 IC50 0.865 0.681 0.861 0.711 0.797 0.592 - - 0.783 0.582 0.173 -0.632 0.802 0.615
DRA*01:01/DRB1*07:01 1071 IC50 0.855 0.687 0.878 0.761 0.871 0.741 0.787 0.553 0.858 0.712 0.190 -0.607 0.861 0.719
DRA*01:01/DRB1*07:01 69 Binary 0.811 0.535 0.876 0.648 0.863 0.626 0.659 0.274 0.847 0.598 0.260 -0.413 0.840 0.587
DRA*01:01/DRB1*08:01 889 IC50 0.808 0.637 0.863 0.719 - - - - - - 0.201 -0.592 0.798 0.591
DRA*01:01/DRB1*08:02 142 IC50 0.752 0.471 0.736 0.439 0.705 0.320 - - 0.385 0.188 0.721 0.411 0.315 -0.154
DRA*01:01/DRB1*09:01 873 IC50 0.853 0.617 0.868 0.697 0.845 0.669 0.595 0.157 0.791 0.574 - - 0.810 0.595
DRA*01:01/DRB1*09:01 34 Binary 0.802 0.523 0.837 0.583 0.839 0.586 0.623 0.219 0.795 0.511 - - 0.759 0.448
DRA*01:01/DRB1*11:01 66 Binary 0.678 0.299 0.749 0.419 0.722 0.373 - - 0.690 0.319 0.294 -0.347 0.742 0.408
DRA*01:01/DRB1*11:01 1006 IC50 0.851 0.694 0.890 0.778 0.870 0.748 - - 0.849 0.714 0.204 -0.602 0.840 0.696
DRA*01:01/DRB1*12:02 17 Binary 0.886 0.659 0.800 0.512 - - - - - - - - - -
DRA*01:01/DRB1*13:01 18 Binary 0.988 0.846 0.864 0.632 - - - - - - 0.228 -0.471 0.772 0.471
DRA*01:01/DRB1*13:01 866 IC50 0.846 0.652 0.772 0.532 - - - - - - 0.210 -0.551 0.790 0.551
DRA*01:01/DRB1*13:02 134 IC50 0.632 0.048 0.903 0.620 0.910 0.606 - - 0.756 0.422 0.720 0.281 0.765 0.527
DRA*01:01/DRB1*14:54 854 IC50 0.867 0.683 0.889 0.713 - - - - - - - - - -
DRA*01:01/DRB1*15:01 167 IC50 0.866 0.621 0.758 0.498 0.744 0.525 - - 0.514 0.057 0.636 0.176 0.469 0.019
DRA*01:01/DRB1*15:01 79 Binary 0.537 0.057 0.578 0.120 0.610 0.169 - - 0.446 -0.082 0.504 0.006 0.517 0.026
DRA*01:01/DRB1*15:02 17 Binary 0.846 0.510 1.000 0.736 - - - - - - 0.173 -0.481 0.827 0.481
DRA*01:01/DRB1*15:02 18 IC50 0.933 0.683 0.667 0.409 - - - - - - 0.444 -0.387 0.544 0.384
DRA*01:01/DRB3*01:01 852 IC50 0.644 0.293 0.838 0.597 0.827 0.546 0.677 0.300 0.808 0.527 - - 0.800 0.484
DRA*01:01/DRB3*02:02 771 IC50 0.725 0.422 0.740 0.432 - - - - - - - - - -
DRA*01:01/DRB3*03:01 854 IC50 0.794 0.568 0.781 0.563 - - - - - - - - - -
DRA*01:01/DRB4*01:01 14 IC50 0.725 0.472 0.800 0.516 0.600 0.402 0.725 0.548 0.725 0.460 - - 0.650 0.465
DRA*01:01/DRB4*01:01 18 Binary 0.615 0.179 0.723 0.347 0.738 0.371 0.492 -0.012 0.554 0.084 - - 0.646 0.227
DRA*01:01/DRB4*01:03 839 IC50 0.832 0.644 0.786 0.539 - - - - - - - - - -
DRA*01:01/DRB5*01:01 18 Binary 0.889 0.636 0.958 0.750 0.917 0.681 - - 0.847 0.568 0.306 -0.318 0.778 0.454
DRA*01:01/DRB5*01:01 762 IC50 0.785 0.596 0.843 0.743 0.806 0.660 - - 0.778 0.609 0.260 -0.526 0.775 0.607






In this dissertation proposal, we introduced our work on mislocation related cancer
genes indentification and peptide-MHC I binding prediction. For the first work,
we showed that our pipeline has the capability to capture misolcation related cancer
genes and gave a list of potential cancers genes that are related to proteins mislocation.
Comparing with other methods, our pipeline only relies on gene expression data. This
makes our pipeline much easier to be applied on other cancers.
In the second part work, our proposed an allele-specific CNN model (DeepMHC)
works better than all existing models. Also we explored on how network structure and
data encoding will effect the performance for peptide-MHC I binding prediction. In
our next work, we presented a pan-specific model (DeepSeqPan) which takes into the
raw sequences of HLA alleles and peptides. In this proposed model, we successfully
let the model learn to encode the protein sequences instead of using knowledge and
structure based pseudo sequence encoding method. Our proposed method offers a
novel encoding and modeling solution on this problem. The benchmark test results
showed that DeepSeqPan can outperform other methods on certain alleles. We argue
that the DeepSeqPan model could be integrated into existing ensemble methods to
improved the overall capabilities. In our final work, we proposed a novel attention-
like LSTM-CNN model on class II HLA binding problem. Our model is the only
available non pseudo sequence based pan-specific model in thia area. Testing with
benchmark dataset, our model achieve state-of-the-art performance and outperformed
other methods on several certain alleles. With the help of attention mechanism, our
model could directly output the binding core prediction. Comparing with existing
binding core prediction, our model predicts based on the whole peptide in one-shot.
Also, it could offer attention weight on each individual position.
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6.2 Future work
6.2.1 Extending DeepSeqPan on dynamic length peptides
In current DeepSeqPan model, we only focus on 9-mers. However, HLA class I could
also bind to 10-, 11-length peptides though not so common as 9-length peptides.
Considering this, in future we plan to extend the DeepSeqPan model to handle variant
peptides input. Right now, we have two options in hand: (i) padding all peptides as
a fixed length input, i.e. 11-length, and (ii) using LSTM to encode peptides input.
We plan to explore both options and test which one offers better performance.
6.2.2 Other binding problems
As we mentioned before, protein related bindings are very common and important
in cell activities. In our work, we focused on HLA-peptide bindings. Other binding
problems, such as DNA-binding protein, protein-protein binding and protein-ligand
binding etc., also need reliable and effective tools to help researchers design their
bench experiment. Since all our proposed method are sequence based without relying
on any structure or domain information, we plan to extend these models to other
protein related binding problems.
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